[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 132
1. Szajda SD, Jankowska A, Zwierz K: Carbohydrate markers in colon carcinoma. Dis Markers; 2008;25(4-5):233-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbohydrate markers in colon carcinoma.
  • Spontaneously mutated multiple oncogenes and/or tumor suppressor genes in colon epithelial cell and its progeny, may cause proliferation out of control and create benign colon neoplasm (colon polyp).
  • If additional mutations involve genes responsible for cell adhesion and movement, aberrant epithelial cells may become malignant (colon cancer) and invade surrounding and remote tissues, creating secondary tumors called metastases.
  • To laboratory detection and monitoring of colon cancer are used tumor markers.
  • Tumor markers are substances produced by the body in response to cancer, or by cancer tissue itself.
  • Glycoconjugate markers for colon cancer include aberrant: mucins covering the surface of the colon epithelial cells, cadherins, selectins and Ig-like adhesion molecules mediating cell-cell adhesion, integrins and integral membrane proteoglycans responsible for adhesion of colon epithelial cells to extracellular matrix, glycoconjugate components of ECM, as well as lysosomal membrane glycoproteins and exoglycosidases.
  • Detection of colon cancer at early non malignant stage is crucial in its prevention and eradication.
  • As colon cancer is the effect of accumulation many somatic mutations in oncogens, supressors, mismatch repair genes and many genes responsible for posttranslational modifications of proteins, multidirectional approach should be applied for its detection.
  • A glycobiological approach to diagnosis and treatment of colorectal cancer should be directed to detection changes in glycosylation accompanying every step of colon cancer progression, and correlation between changes in glycosylation and tumor progression.
  • [MeSH-major] Carbohydrates / chemistry. Carcinoma / metabolism. Colonic Neoplasms / metabolism
  • [MeSH-minor] Aged. Cadherins / chemistry. Cell Adhesion. Disease Progression. Epithelial Cells / metabolism. Glycoproteins / chemistry. Glycoproteins / metabolism. Humans. Middle Aged. Mucins / metabolism. Neoplasm Invasiveness. Neoplasm Metastasis. Polysaccharides / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126967.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / Carbohydrates; 0 / Glycoproteins; 0 / Mucins; 0 / Polysaccharides
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC3827819
  •  go-up   go-down


2. Tobalina Aguirrezábal E, Múgica Alcorta I, Portugal Porras V, Sarabia García S: [Implantation of laparoscopic colon surgery in a general surgery department]. Cir Esp; 2007 Mar;81(3):134-8
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Implantation of laparoscopic colon surgery in a general surgery department].
  • [Transliterated title] Implantación de la cirugía laparoscópica de colon en un servicio de cirugía general.
  • OBJECTIVE: To evaluate the viability, safety and short-term results of laparoscopic colon surgery during the first few years after its introduction in our department.
  • METHOD: Between January 2002 and December 2005, laparoscopic surgery was performed in patients with surgical indication for benign colon disease.
  • Surgery was indicated for benign disease in 60 patients (66%).
  • Distribution was left colon in 79 patients and right colon in 11 patients.
  • CONCLUSIONS: Laparoscopic surgery of the colon is safe and reproducible.
  • [MeSH-major] Colonic Neoplasms / epidemiology. Colonic Neoplasms / surgery. Colonoscopy / methods. Colonoscopy / statistics & numerical data. Surgery Department, Hospital / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Spain / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349237.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Lazaraki G, Tragiannidis D, Xirou P, Nakos A, Pilpilidis I, Katsos I: Endoscopic resection of giant lipoma mimicking colonic neoplasm initially presenting with massive haemorrhage: a case report. Cases J; 2009;2:6462

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection of giant lipoma mimicking colonic neoplasm initially presenting with massive haemorrhage: a case report.
  • Lipomas of the colon are benign tumors that rarely occur.
  • They are usually asymptomatic but occasionally they present with clinical manifestations depending on tumor size, localization and complications, which often lead to diagnostic difficulty.
  • During colonoscopy a giant polyp of over 50 mm in its bigger diameter, with a thick stalk of 2 cm, located in the transverse colon, was revealed.
  • In this report discussion over endoscopic resection of colonic lipomas mimicking neoplasms is also performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1987 Nov;30(11):888-93 [3677966.001]
  • [Cites] Dig Dis Sci. 2008 Oct;53(10):2826-7 [18270829.001]
  • [Cites] Dis Colon Rectum. 1972 Nov-Dec;15(6):441-4 [4645612.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Jul;5(3):713-21 [8829328.001]
  • [Cites] Surg Endosc. 1998 Jan;12(1):42-5 [9419301.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):2143-4 [10950091.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):1295-7 [11316189.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1944-6 [11419863.001]
  • [Cites] Gastrointest Endosc. 2002 Jun;55(7):929-31 [12024158.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):756-9 [15855988.001]
  • [Cites] Gastrointest Endosc. 2005 Dec;62(6):988-90 [16301055.001]
  • [Cites] Indian J Gastroenterol. 2007 Sep-Oct;26(5):254-5 [18227586.001]
  • [Cites] Eur J Surg. 1991 Jan;157(1):51-5 [1675882.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):532-3 [2152245.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):435-8 [2227312.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):509-11 [2227328.001]
  • [Cites] Am Surg. 1985 Aug;51(8):449-54 [4026070.001]
  • (PMID = 20181161.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827102
  •  go-up   go-down


Advertisement
4. Uygun K, Kocak Z, Altaner S, Cicin I, Tokatli F, Uzal C: Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer. Yonsei Med J; 2006 Aug 31;47(4):578-82
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer.
  • We will present an unusual case of colonic metastasis from a carcinoma of the breast that mimics a primary intestinal cancer, along with a through review of English language medical literature.
  • Despite the fact that isolated gastrointestinal (GI) metastases are very rare and much less common than benign disease processes or second primaries of the intestinal tract in patients with a history of breast cancer, metastatic disease should be given consideration whenever a patient experiences GI symptoms.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / secondary. Intestinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Breast / pathology. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):3014-6 [11051411.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):463-4 [12099661.001]
  • [Cites] Am J Dig Dis. 1972 Oct;17(10):881-6 [5073677.001]
  • [Cites] J Surg Oncol. 1979;11(3):193-205 [459515.001]
  • [Cites] Dis Colon Rectum. 1988 May;31(5):401-2 [3366041.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):181-7 [2910416.001]
  • [Cites] Int J Biol Markers. 1988 Jan-Mar;3(1):41-8 [2854832.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):368-72 [2050370.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] Am J Clin Oncol. 1992 Aug;15(4):365-9 [1514536.001]
  • [Cites] J Surg Oncol. 1992 Nov;51(3):211-5 [1434649.001]
  • [Cites] Med Klin (Munich). 1992 Dec 15;87(12):631-6 [1287424.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):681-2 [10919011.001]
  • (PMID = 16941751.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687742
  •  go-up   go-down


5. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer; 2008;7:94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
  • BACKGROUND: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact.
  • This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
  • Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-, KRAS-, and TP53 mutation status.
  • RESULTS: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
  • The promoters of ADAMTS1, MAL, and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability.
  • In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes.
  • CONCLUSION: Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA Methylation. Early Detection of Cancer. Genes, Neoplasm. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Aged, 80 and over. Cluster Analysis. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Middle Aged. Promoter Regions, Genetic. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9107-16 [17909015.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S7-9 [18023574.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] J Transl Med. 2008;6:13 [18346269.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):270-7 [18437011.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1571-6 [18497967.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1290-301 [18486467.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):799-803 [11440966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33 [15194513.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2078-85 [16033773.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Genome Res. 2006 Feb;16(2):282-9 [16369045.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):17-23 [16531764.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Pathol Res Pract. 2006;202(6):415-24 [16675157.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):429-35 [16820927.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9 [16872319.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10664-70 [17090521.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Hum Genet. 2007 Jan;120(5):701-11 [17024368.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):950-4 [17352030.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1421-7 [17487400.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]
  • (PMID = 19117505.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2639620
  •  go-up   go-down


6. Hong R, Lim SC: Granular cell tumor of the cecum with extensive hyalinization and calcification: a case report. World J Gastroenterol; 2009 Jul 14;15(26):3315-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the cecum with extensive hyalinization and calcification: a case report.
  • A granular cell tumor (GCT) is a benign neoplasm of unclear histogenesis that is generally believed to be of nerve sheath origin.
  • In addition to the tumor, endoscopic examination revealed the presence of a 5-mm-polyp in the descending colon and multiple tiny polyps in the sigmoid colon and rectum.
  • Histological examination demonstrated a cecal tumor 1.5 cm x 1.0 cm x 0.7 cm with a hard consistency; in cut sections, mixed cells with yellowish and whitish portions were seen.
  • The tumor was located between the mucosa and subserosa, and was composed of plump histiocyte-like tumor cells with abundant granular eosinophilic cytoplasm, which were immunoreactive for S-100 protein, vimentin, neuron-specific enolase, inhibin-alpha and calretinin.
  • The tumor showed extensive hyalinization and focal dystrophic calcification.
  • Extensive hyalinization and calcification showing involution of tumor cells suggest benign clinical behavior of GCT.
  • [MeSH-major] Calcinosis / pathology. Cecum / pathology. Granular Cell Tumor / pathology. Hyalin / metabolism
  • [MeSH-minor] Biomarkers, Tumor. Calbindin 2. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Humans. Male. Middle Aged. Phosphopyruvate Hydratase. S100 Calcium Binding Protein G. S100 Proteins. Vimentin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ugeskr Laeger. 2006 May 22;168(21):2080-1 [16768929.001]
  • [Cites] J Oral Pathol Med. 1997 Apr;26(4):164-9 [9176790.001]
  • [Cites] J Craniofac Surg. 2008 Nov;19(6):1691-4 [19098584.001]
  • [Cites] J Oral Pathol Med. 2009 Jan;38(1):150-9 [19192059.001]
  • [Cites] J Gastroenterol. 2000;35(8):631-4 [10955603.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1200-3 [11688581.001]
  • [Cites] J Gastroenterol. 2003;38(4):385-9 [12743780.001]
  • [Cites] World J Gastroenterol. 2004 Aug 15;10(16):2452-4 [15285042.001]
  • [Cites] Mt Sinai J Med. 1979 Mar-Apr;46(2):195-8 [220528.001]
  • [Cites] J Surg Oncol. 1980;13(4):301-16 [6246310.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Apr;65(4):427-35 [2834681.001]
  • [Cites] Am J Gastroenterol. 1989 Jun;84(6):656-9 [2543214.001]
  • [Cites] Am J Gastroenterol. 1993 Feb;88(2):311-5 [8424442.001]
  • [Cites] Am J Gastroenterol. 1993 Oct;88(10):1785-7 [8213726.001]
  • [Cites] Pathologica. 1995 Apr;87(2):175-8 [8532413.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Dec;80(6):687-97 [8680977.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1997 Jan;94(1):27-32 [9028140.001]
  • [Cites] Turk J Gastroenterol. 2008 Mar;19(1):73-4 [18386247.001]
  • (PMID = 19598311.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / S100 Proteins; 0 / Vimentin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Other-IDs] NLM/ PMC2710791
  •  go-up   go-down


7. Rimkus C, Martini M, Friederichs J, Rosenberg R, Doll D, Siewert JR, Holzmann B, Janssen KP: Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer; 2006 Nov 20;95(10):1419-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer.
  • The gene SASH1 (SAM- and SH3-domain containing 1) has originally been identified as a candidate tumour suppressor gene in breast cancer.
  • We have used quantitative real-time PCR to investigate the expression of SASH1 in tissue samples from 113 patients with colon carcinoma, and compared the expression with 15 normal colon tissue samples.
  • Moreover, nine benign adenomas and 10 liver metastases were analysed.
  • Expression levels of SASH1 were strongly and significantly reduced in colon cancer of UICC stage II, III, and IV, as well as in liver metastases.
  • Overall, 48 out of 113 primary colon tumours showed SASH1 expression that was at least 10-fold lower than the levels found in normal colon tissue.
  • [MeSH-major] Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Colon / metabolism. Colon / pathology. Down-Regulation. Female. Genes, Tumor Suppressor. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 2001 Jul 30;1520(1):89-93 [11470164.001]
  • [Cites] Cell Immunol. 2005 May;235(1):46-55 [16137664.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5373-7 [11536050.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 19;288(1):137-41 [11594764.001]
  • [Cites] Nat Struct Biol. 2002 Jun;9(6):453-7 [11992127.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2972-83 [12771949.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):369-80 [12800148.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22118-23 [15037605.001]
  • [Cites] Fam Cancer. 2004;3(2):93-100 [15340259.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):737-47 [15381729.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Nature. 1995 Feb 16;373(6515):573-80 [7531822.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9646-60 [16227612.001]
  • [Cites] EMBO J. 2001 Aug 1;20(15):4173-82 [11483520.001]
  • (PMID = 17088907.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / SASH1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2360597
  •  go-up   go-down


8. Törnroos A, Garvin S, Olsson H: The number of identified lymph node metastases increases continuously with increased total lymph node recovery in pT3 colon cancer. Acta Oncol; 2009;48(8):1152-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The number of identified lymph node metastases increases continuously with increased total lymph node recovery in pT3 colon cancer.
  • BACKGROUND. The positive correlation between the number of recovered benign lymph nodes and patient prognosis is well established for stage II colon cancer patients.
  • This study aims to investigate the association between the total lymph node harvest and the number of lymph node metastases in colon cancer specimen.
  • We studied the original pathology reports of 649 patients diagnosed with T3 adenocarcinoma of the colon at the Department of Clinical Pathology and Genetics at Linköping University Hospital, Linköping, Sweden between the years 2000 and 2008.
  • Rather than focusing on a recommended minimum number of nodes, efforts should be shifted towards developing methods assuring that colon cancer specimen are dissected in a standardized way that optimizes the lymph node harvest.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863223.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Bacci G, Ferrari C, Longhi A, Ferrari S, Forni C, Bacchini P, Palmerini E, Briccoli A, Pignotti E, Balladelli A, Picci P: Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol; 2006 Dec;28(12):774-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy.
  • Twenty-six patients (2.15%) developed a second malignant neoplasm at a median of 7.6 years (1 to 25 y) after primary osteosarcoma treatment.
  • Second neoplasms were leukemia (10), breast (7), lung (2), kidney (2), central nervous system cancer (2), soft tissue (1), parotid (1), and colon (1).
  • The rate of second neoplasms was significantly higher in female patients, and the latent period shorter in hematologic tumors compared with solid tumors.
  • The rate of second malignancies observed in the osteosarcoma group was significantly higher than that observed in the control group of 1160 patients with benign tumors treated in the same period at our Institute (2.2% vs. 0.8%, P<0.009).
  • Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164644.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Willis S, Schumpelick V: [Open colon surgery]. Chirurg; 2005 Nov;76(11):1073-81
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Open colon surgery].
  • Open resection of the colon is one of the most frequent abdominal operations, which clearly indicates the great importance of colon carcinomas.
  • In this respect, the techniques employed are strictly standardized: right hemicolectomy for right colon carcinoma, transverse resection for right colon carcinoma, left hemicolectomy for descendent colon carcinoma, and sigmoid resection for sigmoid carcinoma.
  • In case of benign underlying disease, the operational method depends largely on the extent to which the intestine is affected and can include anything from simple colotomy and polyp removal to colectomy for toxic megacolon.
  • Elective colon surgery is usually primary, but in emergencies a protective stoma might be necessary.
  • Standardized indication and operational techniques enable low perioperative mortality and complication rates that make open colon resection usually un-problematic even in very old patients.
  • [MeSH-minor] Anastomosis, Surgical / methods. Colon / pathology. Colonic Polyps / mortality. Colonic Polyps / pathology. Colonic Polyps / surgery. Humans. Neoplasm Invasiveness / pathology. Neoplasm Staging. Postoperative Complications / mortality. Surgical Staplers. Surgical Wound Dehiscence / mortality. Survival Analysis. Suture Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1988 May;75(5):409-15 [3292002.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):271-7; discussion 277-8 [14991487.001]
  • [Cites] Dis Colon Rectum. 1990 Jul;33(7):610-4 [2361432.001]
  • [Cites] Dis Colon Rectum. 1994 Jul;37(7):651-9 [8026230.001]
  • [Cites] Chirurg. 2004 Nov;75(11):1071-8 [15316639.001]
  • (PMID = 16240155.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution.
  • PURPOSE: Endoscopically unresectable apparently benign colorectal polyps are considered by some surgeons as ideal for their early laparoscopic colectomy experience.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • METHODS: Data from a consecutive series of patients undergoing laparoscopic colectomy (on an intention-to-treat basis) for endoscopically unresectable neoplasms with benign preoperative histology were retrieved from a prospective database and supplemented by chart review.
  • The median nodal harvest was 12 and all resection margins were free of neoplasm.
  • Mean diameter of benign tumors was 3.2 cm (range 0.5-10.0cm) versus 3.9cm (range 1.5-7.5cm) for adenocarcinomas (p = 0.189, t - test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Ann Surg. 1979 Dec;190(6):679-83 [518167.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] AORN J. 1992 Dec;56(6):1068-73 [1463326.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Majewska U, Banaś D, Braziewicz J, Góźdź S, Kubala-Kukuś A, Kucharzewski M: Trace element concentration distributions in breast, lung and colon tissues. Phys Med Biol; 2007 Jul 7;52(13):3895-911
Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trace element concentration distributions in breast, lung and colon tissues.
  • The concentrations of Fe, Cu, Zn and Se in cancerous and benign tissues of breast, lung and intestine (colon) have been determined.
  • Finally, the log-rank test has been applied to compare the elemental concentration distributions between cancerous and benign tissues of the same organ, between cancerous tissues and between benign tissues taken from different organs.
  • Comparing benign and malignant neoplastic tissues, statistically significant differences have been found between Fe and Se concentration distributions of breast as well as for Cu and Zn in the case of lung tissues and in the case of colon tissues for Zn.
  • The concentrations of all elements have been found to be statistically different in cancer tissues as well as in benign ones when comparing the different organs, i.e. groups 'breast-colon' and 'breast-lung'.
  • Concentrations of Fe and Cu have been found to be statistically different in lung and colon cancerous tissues.
  • For benign tissues of lung and colon a statistically significant difference has been found only for Zn.
  • [MeSH-major] Breast / metabolism. Breast Neoplasms / metabolism. Colon / metabolism. Colonic Neoplasms / metabolism. Lung / metabolism. Lung Neoplasms / metabolism. Spectrometry, X-Ray Emission / methods. Trace Elements / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Iron / chemistry. Male. Middle Aged. Neoplasm Metastasis. Selenium / chemistry. Zinc / chemistry

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17664584.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Trace Elements; E1UOL152H7 / Iron; H6241UJ22B / Selenium; J41CSQ7QDS / Zinc
  •  go-up   go-down


13. Sasaki Y, Niwa Y, Hirooka Y, Ohmiya N, Itoh A, Ando N, Miyahara R, Furuta S, Goto H: The use of endoscopic ultrasound-guided fine-needle aspiration for investigation of submucosal and extrinsic masses of the colon and rectum. Endoscopy; 2005 Feb;37(2):154-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of endoscopic ultrasound-guided fine-needle aspiration for investigation of submucosal and extrinsic masses of the colon and rectum.
  • The aim of this study was to evaluate the use of EUS-FNA for the diagnosis of lesions either within or adjacent to the wall of the colon and rectum.
  • PATIENTS AND METHODS: A total of 22 patients with a lesion within the wall of, or adjacent to, the colon or rectum underwent EUS-FNA.
  • In the four patients who had lesions located proximal to the sigmoid colon, EUS-FNA was performed using a guide wire and overtube.
  • The success rates for adequate tissue sampling and for detecting malignant and benign masses by EUS-FNA were evaluated and the success rate for detection was compared with the success rate of EUS and computed tomography.
  • The overall rate of detection of malignant and benign masses was 95.5 % (21/22) for EUS-FNA and 81.8 % (18/22) for pre-EUS-FNA imaging investigations.
  • Of the 11 patients in the previous +ve group, ten were diagnosed with recurrences of primary malignancies; of the 11 patients in the previous -ve group, four were diagnosed with primary malignancies and seven were diagnosed with benign lesions.
  • CONCLUSIONS: EUS-FNA is a safe technique which is useful in the planning of treatment for patients who have a mass within the wall or adjacent to the wall of the entire length of the colon or rectum.
  • [MeSH-major] Biopsy, Fine-Needle. Colonic Neoplasms / pathology. Endosonography. Neoplasm Recurrence, Local / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692931.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology; 2009;41(4):366-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, some studies have suggested that SIRT1 could be over-expressed in breast, prostate and colon cancers and up-regulated SIRT1 inactivates p53 by deacetylation.
  • METHODS: Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.
  • RESULTS: Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001).
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sirtuins / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Sirtuin 1. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404850.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


15. Di Valentino M, Menafoglio A, Mazzucchelli L, Siclari F, Gallino A: Rapid-growing left intraventricular cardiac hemangioma. J Am Soc Echocardiogr; 2006 Jul;19(7):939.e5-7
Genetic Alliance. consumer health - Hemangioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 62 years old man with Child B liver cirrhosis, prostate cancer and a recent colon carcinoma resection was referred to our cardiology department for trans-thoracic-echocardiography (TTE) in order to establish left ventricular function before starting chemotherapy.
  • At follow-up TTE showed growing of the intra-cardiac tumor up to 27 x 10 mm, corresponding to a size increase of 1 mm/month.
  • Among different pathologies a rapid growing benign tumor with a high risk of systemic embolisation or an endocardial blood cyst were retained as possible diagnoses.
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825010.001).
  • [ISSN] 1097-6795
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Zhang S, Lin QD, DI W: Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):522-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of BRMS1 messenger RNA (mRNA) in multitissue including normal prostate, ovarian, testis, and colon has been detected by northern blot analysis.
  • We hypothesize that the role of BRMS1 in tumor progression may not be limited to breast cancer and melanoma.
  • We previously found that BRMS1 mRNA levels in primary ovarian epithelial carcinomas were significantly lower than that in normal ovarian and benign tumors (P < 0.05), and statistical analysis of BRMS1 mRNA levels revealed that BRMS1 mRNA levels were significantly higher in early tumor stages (I, II) compared with advanced tumor stages (III, IV) in which lymph node or distant metastases were present (P < 0.01).
  • Therefore, we transfected BRMS1 plasmid into highly malignant ovarian carcinoma cell line, HO-8910PM, and examined cell biologic behaviors including proliferation, adhesion, invasion, and metastasis in vitro and in vivo.
  • BRMS1 expression did not alter the proliferation of HO-8910PM cells in vitro and primary tumor formation in vivo.
  • But, BRMS1 expression significantly suppressed the cell adhesion to extracellular matrix components and in vitro cell invasion in BRMS1-transfected HO-8910PM cells compared to parental HO-8910PM and vector-only transfectants (HO-8910PM-vect).
  • Also, BRMS1 transfectants form significantly less metastatic to organs of peritoneal cavity in orthotopically implanted ovarian tumor nude models.
  • [MeSH-major] Gene Expression Regulation / physiology. Neoplasm Proteins / physiology. Ovarian Neoplasms / prevention & control
  • [MeSH-minor] Animals. Cell Movement. Cell Proliferation. Disease Models, Animal. Down-Regulation. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Invasiveness. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / prevention & control. Neoplasms, Glandular and Epithelial / secondary. Peritoneal Neoplasms / prevention & control. Peritoneal Neoplasms / secondary. RNA, Messenger / metabolism. Repressor Proteins. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Tumor Cells, Cultured. Tumor Stem Cell Assay

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681721.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRMS1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins
  •  go-up   go-down


17. Low SY, Eng P, Keng GH, Ng DC: Positron emission tomography with CT in the evaluation of non-small cell lung cancer in populations with a high prevalence of tuberculosis. Respirology; 2006 Jan;11(1):84-9
MedlinePlus Health Information. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One proved to be benign whereas the other was consistent with metastasis.
  • Two patients with positive PET-CT for lesions in the colon turned out to be benign histologically.
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity. Singapore


18. Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC: Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol; 2005 Oct 1;23(28):6846-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologic examinations of these 32 lesions revealed a second clinically unsuspected malignancy or a recurrence of a previous diagnosed carcinoma in six patients (19%) and a benign tumor or inflammatory lesion in 26 patients (81%).
  • Benign tumors and inflammatory lesions included eight colon adenomas, four Warthin's tumors, one granuloma of the lower jaw, one adenoma of the thyroid gland, one compensatory muscle activity due to vocal chord palsy, two occurrences of arthritis, three occurrences of reflux esophagitis, two occurrences of pancreatitis, two occurrences of diverticulitis, one hemorrhoidal inflammation, and one rib fracture.
  • CONCLUSION: Solitary extrapulmonary FDG accumulations in patients with newly diagnosed lung cancer should be analyzed critically for correct staging and optimal therapy, given that up to half of the lesions may represent unrelated malignancies or benign disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Neoplasm Metastasis / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Inflammation. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192576.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


19. Bettstetter M, Woenckhaus M, Wild PJ, Rümmele P, Blaszyk H, Hartmann A, Hofstädter F, Dietmaier W: Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol; 2005 Apr;205(5):606-14
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer.
  • Significant upregulation of maspin expression was found in MSI-H tumours compared to both MSS/MSI-L tumours and matched benign colonic mucosa.
  • Increased maspin expression was also found in three MSI-H colon cancer cell lines, but not in three MSS colon cancer cell lines by RT-PCR and western blot analyses.
  • Intense nuclear maspin immunostaining was seen specifically in MSI-H tumours (p = 0.013), de-differentiated tumours (p = 0.006), and at the invasion front.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Microsatellite Repeats. Neoplasm Proteins / metabolism. Serpins / metabolism
  • [MeSH-minor] Blotting, Western. Cell Nucleus / metabolism. CpG Islands. Cytoplasm / metabolism. DNA Methylation. DNA, Neoplasm / genetics. Genes, Tumor Suppressor. Humans. Neoplasm Invasiveness. Neoplasm Staging. Promoter Regions, Genetic. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Transcription, Genetic

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714592.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


20. Nishio J, Nabeshima K, Iwasaki H, Naito M: Non-traumatic myositis ossificans mimicking a malignant neoplasm in an 83-year-old woman: a case report. J Med Case Rep; 2010;4:270
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-traumatic myositis ossificans mimicking a malignant neoplasm in an 83-year-old woman: a case report.
  • INTRODUCTION: Myositis ossificans is a benign, self-limiting condition that usually affects young, athletically active men.
  • She had a history of surgery for transverse colon cancer and lung cancer at the ages of 73 and 80, respectively.
  • Clinical and radiological examinations suggested a malignant neoplasm such as metastatic carcinoma or extraskeletal osteosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2008 Jan 1;112(1):193-203 [18040999.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Apr;263(4):331-5 [16133463.001]
  • [Cites] Clin Orthop Relat Res. 1998 Oct;(355):272-81 [9917613.001]
  • [Cites] Clin Radiol. 1995 Oct;50(10):730-1 [7586971.001]
  • [Cites] Clin Radiol. 2002 Dec;57(12):1058-66 [12475528.001]
  • [Cites] Pediatr Pathol. 1992 Mar-Apr;12(2):223-9 [1570239.001]
  • [Cites] Skeletal Radiol. 1992;21(2):87-101 [1566115.001]
  • [Cites] Acta Pathol Jpn. 1985 Sep;35(5):1109-22 [3866484.001]
  • [Cites] Clin Orthop Relat Res. 1993 Nov;(296):213-7 [8222429.001]
  • (PMID = 20704714.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2928249
  •  go-up   go-down


21. Obtulowicz T, Swoboda M, Speina E, Gackowski D, Rozalski R, Siomek A, Janik J, Janowska B, Ciesla JM, Jawien A, Banaszkiewicz Z, Guz J, Dziaman T, Szpila A, Olinski R, Tudek B: Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients. Mutagenesis; 2010 Sep;25(5):463-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients.
  • Oxidative stress is involved in the pathogenesis of colon cancer.
  • In the examined groups of patients with colorectal cancer (CRC, n = 89), benign adenoma (AD, n = 77) and healthy volunteers (controls, n = 99), we measured: vitamins A, C and E in blood plasma, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydroguanine (8-oxoGua) in leukocytes and urine, leukocyte 8-oxoGua excision activity, mRNA levels of APE1, OGG1, 8-oxo-7,8-dihydrodeoxyguanosine 5'-triphosphate pyrophosphohydrolase (MTH1) and OGG1 polymorphism.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. DNA Repair / genetics. Deoxyguanosine / analogs & derivatives. Oxidative Stress / genetics
  • [MeSH-minor] Adenomatous Polyps / blood. Adenomatous Polyps / metabolism. Adult. Aged. Aging / genetics. Antioxidants / metabolism. Case-Control Studies. DNA Glycosylases / genetics. DNA Glycosylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. DNA, Neoplasm / metabolism. DNA-(Apurinic or Apyrimidinic Site) Lyase / genetics. DNA-(Apurinic or Apyrimidinic Site) Lyase / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Phosphoric Monoester Hydrolases / genetics. Phosphoric Monoester Hydrolases / metabolism. Polymorphism, Single Nucleotide / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Sex Characteristics. Smoking / adverse effects. Smoking / genetics

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534734.001).
  • [ISSN] 1464-3804
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / DNA, Neoplasm; 0 / RNA, Messenger; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.6.- / 8-oxodGTPase; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; EC 4.2.99.18 / APEX1 protein, human; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase; EC 6.5.1.- / DNA Repair Enzymes; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


22. Zarkovic K, Uchida K, Kolenc D, Hlupic L, Zarkovic N: Tissue distribution of lipid peroxidation product acrolein in human colon carcinogenesis. Free Radic Res; 2006 Jun;40(6):543-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue distribution of lipid peroxidation product acrolein in human colon carcinogenesis.
  • It suppresses p53 synthesis acting as potent carcinogenic factor for oral, respiratory and bladder carcinomas, while its possible association with colon carcinogenesis was not studied so far.
  • We used genuine monoclonal antibody to evaluate immunohistochemical distribution of acrolein-protein adducts in 113 human colon tumours.
  • The presence of acrolein-protein adducts was increasing with respect to colon carcinogenesis, from moderate appearance in tubular and villotubular low-grade adenomas to abundant and diffuse distribution in high-grade villotubular adenomas and Dukes A carcinomas.
  • However, in advanced Dukes B and C carcinomas acrolein was hardly noticed, although, its protein adducts were found abundant in non-malignant colon epithelium of these patients.
  • According to these findings, acrolein seems to be lipid peroxidation product associated with transition from benign into malignant colon tumours.
  • [MeSH-major] Acrolein / metabolism. Colonic Neoplasms / metabolism. Lipid Peroxidation
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Tissue Distribution

  • Hazardous Substances Data Bank. ACROLEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753831.001).
  • [ISSN] 1071-5762
  • [Journal-full-title] Free radical research
  • [ISO-abbreviation] Free Radic. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7864XYD3JJ / Acrolein
  •  go-up   go-down


23. Loungnarath R, Mutch MG, Birnbaum EH, Read TE, Fleshman JW: Laparoscopic colectomy using cancer principles is appropriate for colonoscopically unresectable adenomas of the colon. Dis Colon Rectum; 2010 Jul;53(7):1017-22
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy using cancer principles is appropriate for colonoscopically unresectable adenomas of the colon.
  • PURPOSE: This study was undertaken to determine the risks of cancer in unresectable polyps and to compare the short-term outcome of laparoscopic colectomy with that of open colectomy for benign polyps.
  • Oncologic resection of the colon should be performed for all colonoscopically unresectable polyps due to the risk of cancer.
  • [MeSH-major] Adenoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Colonoscopy / contraindications. Laparoscopy / methods
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551753.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Benarroch-Gampel J, Riall TS: Extrapancreatic malignancies and intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg; 2010 Oct 27;2(10):363-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gastrointestinal tract is most commonly involved in secondary malignancies, with benign colon polyps and colon cancer commonly seen in western countries and gastric cancer commonly seen in Asian countries.
  • Other extrapancreatic malignancies associated with IPMNs include benign and malignant esophageal neoplasms, gastrointestinal stromal tumors, carcinoid tumors, hepatobiliary cancers, breast cancers, prostate cancers, and lung cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160845.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999205
  • [Keywords] NOTNLM ; Intraductal papillary mucinous neoplasm / Invasive / Malignant potential / Non-invasive / Secondary malignancy
  •  go-up   go-down


25. Seo GJ, Sohn DK, Han KS, Hong CW, Kim BC, Park JW, Choi HS, Chang HJ, Oh JH: Recurrence after endoscopic piecemeal mucosal resection for large sessile colorectal polyps. World J Gastroenterol; 2010 Jun 14;16(22):2806-11
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 50 polyps identified, 34 (68%) were benign and 16 (32%) were malignant.
  • The recurrence rate after EPMR was 3.1% for benign polyps and 33.3% for malignant polyps (P < 0.05).
  • [MeSH-major] Colonic Polyps / pathology. Colonic Polyps / surgery. Endoscopy, Gastrointestinal / methods. Intestinal Mucosa / pathology. Neoplasm Recurrence, Local / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Jun;51(6):697-700 [10840302.001]
  • [Cites] J Gastroenterol Hepatol. 2010 Jan;25(1):84-9 [19793173.001]
  • [Cites] Endoscopy. 2003 Mar;35(3):212-8 [12584639.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):340-8 [12626909.001]
  • [Cites] Endoscopy. 2003 Aug;35(8):S41-4 [12929053.001]
  • [Cites] Gut. 2004 Apr;53(4):568-72 [15016753.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):234-41 [15278051.001]
  • [Cites] Am J Gastroenterol. 1977 May;67(5):430-8 [900105.001]
  • [Cites] Gastrointest Endosc. 1984 Feb;30(1):18-20 [6706083.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):128-32 [2032596.001]
  • [Cites] Gastrointest Endosc. 1992 May-Jun;38(3):303-9 [1607080.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Gastrointest Endosc. 1999 Jun;49(6):731-5 [10343218.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s283-90 [15666108.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):34-41 [16012932.001]
  • [Cites] CA Cancer J Clin. 2006 May-Jun;56(3):143-59; quiz 184-5 [16737947.001]
  • [Cites] Dig Dis Sci. 2007 Mar;52(3):840-4 [17253129.001]
  • [Cites] Gastrointest Endosc. 2007 Jul;66(1):100-7 [17591481.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):229-51, ix [18313548.001]
  • [Cites] World J Gastroenterol. 2008 Apr 21;14(15):2364-9 [18416463.001]
  • [Cites] World J Gastroenterol. 2008 Jul 21;14(27):4289-95 [18666315.001]
  • [Cites] Gastrointest Endosc. 2008 Sep;68(3):615 [18760188.001]
  • [Cites] J Gastroenterol. 2008;43(9):641-51 [18807125.001]
  • [Cites] Surg Endosc. 2010 Feb;24(2):343-52 [19517168.001]
  • [Cites] Br J Surg. 2002 Aug;89(8):1020-4 [12153628.001]
  • (PMID = 20533602.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2883138
  •  go-up   go-down


26. Handisurya A, Rieger A, Bago-Horvath Z, Schellenbacher C, Bankier A, Salat A, Stingl G, Kirnbauer R: Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient. Sex Transm Infect; 2009 Aug;85(4):261-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient.
  • BACKGROUND: Buschke-Löwenstein tumour (BLT) of the anogenitalia is a locally invasive, destructively growing verrucous carcinoma that does not metastasise.
  • Histologically BLT resembles benign condylomata acuminata.
  • Nevertheless, the tumour grows relentlessly and may rarely progress into squamous cell cancer (SCC).
  • Six months later, the tumour had progressed into an ulcerated SCC that destroyed the rectum and perineum, with metastases to the inguinal lymph nodes.
  • Whereas highly active antiretroviral therapy (HAART) effectively suppressed HIV replication, radiochemotherapy plus anti-EGFR antibody did not halt tumour progression, and the patient died from tumour-cachexia.
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. Anti-HIV Agents / therapeutic use. Cachexia / etiology. Fatal Outcome. Groin. HIV Seropositivity / drug therapy. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness


27. Yamamoto H, Okumura K, Toshima S, Mukaisho K, Sugihara H, Hattori T, Kato M, Asano S: FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues. Biol Pharm Bull; 2009 Jul;32(7):1148-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues.
  • FXYD3, also known as Mat-8 (Mammary tumor 8 kDa), is one of mRNAs highly expressed in mouse and human breast cancers.
  • Here, we newly found that FXYD3 protein was also overexpressed in human breast cancer specimens; invasive ductal carcinomas and intra-ductal carcinomas, whereas its expression was low in benign lesion specimens; mastopathy, fibroadenoma and phyllodes tumors.
  • Here, we found that FXYD3a mRNA is a major transcript product expressed in human normal tissues as well as in breast, colon, stomach and pancreas cancer cell lines.
  • [MeSH-major] Breast Neoplasms / metabolism. Cell Proliferation. Membrane Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Blotting, Western. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction. Sequence Alignment. Transfection

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19571376.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / FXYD3 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


28. Ooi BS, Quah HM, Fu CW, Eu KW: Laparoscopic high anterior resection with natural orifice specimen extraction (NOSE) for early rectal cancer. Tech Coloproctol; 2009 Mar;13(1):61-4
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pneumoperitoneum was created, followed by medial-tolateral mobilization of the sigmoid colon, and take down of the splenic flexure and division of the inferior mesenteric vessels laparoscopically.
  • The upper rectum distal to the tumour and proximal colon was transected with a laparoscopic stapler.
  • The proximal colon was then delivered transanally and the anvil of the circular stapler inserted before returning it to the pelvic cavity.
  • This procedure may be applicable to benign tumours and early colorectal cancer, and serves as an intermediate step between laparoscopic and natural orifice surgery.
  • [MeSH-major] Colectomy / methods. Colon / surgery. Laparoscopy / methods. Polyps / surgery. Rectal Neoplasms / surgery. Rectum / surgery
  • [MeSH-minor] Anastomosis, Surgical. Colonoscopy. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1993 Jan-Feb;17(1):51-6 [8447141.001]
  • [Cites] Gastrointest Endosc. 2007 Dec;66(6):1243-5 [17892873.001]
  • [Cites] Dis Colon Rectum. 2000 Oct;43(10 Suppl):S94-7 [11052484.001]
  • [Cites] Tech Coloproctol. 2008 Sep;12(3):251-4 [18679569.001]
  • [Cites] Tech Coloproctol. 2004 Aug;8(2):85-8 [15309643.001]
  • [Cites] Br J Surg. 2003 Apr;90(4):445-51 [12673746.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1120-4 [18481149.001]
  • [Cites] Surg Endosc. 2007 Oct;21(10):1870-4 [17705068.001]
  • [Cites] Br J Surg. 2001 Jun;88(6):801-7 [11412248.001]
  • [Cites] Surg Endosc. 2007 Sep;21(9):1679 [17593441.001]
  • [Cites] Tech Coloproctol. 2002 Apr;6(1):1-4 [12077633.001]
  • [Cites] Dis Colon Rectum. 1994 Mar;37(3):268-71 [8137674.001]
  • (PMID = 19288243.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


29. Chung WC, Kim HK, Yoo JY, Lee JR, Lee KM, Paik CN, Jang UI, Yang JM: Colonic lymphangiomatosis associated with anemia. World J Gastroenterol; 2008 Oct 7;14(37):5760-2
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic lymphangiomatosis associated with anemia.
  • Multiple colonic lymphangioma named as lymphangiomatosis is considered an extremely rare disease.
  • Although lymphangioma is a benign tumor and most colonic lymphangiomas do not cause symptoms and do not require treatment, resection of lymphangioma is necessary in the presence of symptoms such as abdominal pain, bleeding, intussusceptions.
  • We report a case of colonic lymphangiomatosis in a man who presented with abdominal discomfort and anemia, which was diagnosed and treated with endoscopic snare polypectomy.
  • [MeSH-major] Anemia / etiology. Colonic Neoplasms / complications. Lymphangioma / complications

  • Genetic Alliance. consumer health - Lymphangiomatosis.
  • Genetic Alliance. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2000;6(2):146-8 [10936792.001]
  • [Cites] Gastrointest Endosc. 2000 Dec;52(6):781-4 [11115919.001]
  • [Cites] J Nippon Med Sch. 2001 Jun;68(3):262-5 [11404774.001]
  • [Cites] J Gastroenterol. 2002;37(5):381-6 [12051538.001]
  • [Cites] Surg Today. 2002;32(8):734-7 [12181728.001]
  • [Cites] J Gastroenterol. 2003;38(2):181-5 [12640534.001]
  • [Cites] Am J Dig Dis. 1975 Nov;20(11):1076-80 [1200000.001]
  • [Cites] Arch Surg. 1985 Nov;120(11):1266-9 [4051731.001]
  • [Cites] Radiology. 1994 Sep;192(3):697-702 [8058936.001]
  • [Cites] Gastrointest Endosc. 1995 Mar;41(3):252-4 [7789688.001]
  • [Cites] Gastrointest Endosc. 1997 Feb;45(2):204-6 [9041015.001]
  • [Cites] J Clin Gastroenterol. 1997 Apr;24(3):186-7 [9179742.001]
  • [Cites] J Clin Gastroenterol. 1997 Jul;25(1):383-6 [9412929.001]
  • [Cites] J Gastroenterol. 1999 Aug;34(4):520-4 [10452688.001]
  • [Cites] Dig Dis Sci. 2005 Sep;50(9):1747-53 [16133983.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2006 Oct;16(5):530-3 [17004884.001]
  • (PMID = 18837097.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2748215
  •  go-up   go-down


30. Thorat MA, Morimiya A, Mehrotra S, Konger R, Badve SS: Prostanoid receptor EP1 expression in breast cancer. Mod Pathol; 2008 Jan;21(1):15-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EP1 has also been shown to decrease the incidence of colon cancer in mouse models.
  • Expression of EP1 was analysed in breast (benign and cancer) cell lines by reverse-transcriptase polymerase chain reaction and by western blot analyses.
  • The data were compared with and correlated with other prognostic factors like tumour size, tumour grade, lymph node status, oestrogen receptor, progesterone receptor (PR), HER2/neu and cyclooxygenase-2.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Receptors, Prostaglandin E / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Cell Nucleus / chemistry. Cyclooxygenase 2 / analysis. Cytoplasm / chemistry. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Receptors, Prostaglandin E, EP1 Subtype. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906615.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 37403; United States / NIAMS NIH HHS / AR / K08 AR
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PTGER1 protein, human; 0 / Ptger1 protein, mouse; 0 / Ptger1 protein, rat; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP1 Subtype; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


31. Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM, Garzotto M: Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem Biophys Res Commun; 2005 Jul 8;332(3):800-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Targeting of cyclooxygenase-2 (COX-2) for cancer chemoprevention is well supported for several tumor types, most notably colon cancer.
  • Thus, we compared the COX-2 expression, activity, and effects of inhibition in prostate cancer cells on COX-2-dependent colon cancer cells.
  • COX-2 levels in benign and malignant human prostate tissue were determined by immunohistochemistry.
  • Compared to colon cancer cells, prostate cancer cells expressed lower levels of COX-2, produced less PGE2, and were resistant to selective COX-2 inhibition.
  • Examination of benign prostatic epithelium from prostatectomy samples demonstrated rare foci of COX-2.
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Colonic Neoplasms / metabolism. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Dinoprostone / biosynthesis. Drug Resistance, Neoplasm. Humans. Immunohistochemistry. Male. Membrane Proteins. Nitrobenzenes / pharmacology. Sulfonamides / pharmacology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907789.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 69533
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Membrane Proteins; 0 / Nitrobenzenes; 0 / Sulfonamides; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


32. Nonose R, Priolli DG, Cardinalli IA, Máximo FR, Galvão PS, Martinez CA: Epithelioid hemangioma of the colon: a case report. Sao Paulo Med J; 2008 Sep;126(5):294-6
MedlinePlus Health Information. consumer health - Birthmarks.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid hemangioma of the colon: a case report.
  • CONTEXT: Epithelioid hemangioma or angiolymphoid hyperplasia with eosinophilia is an uncommon benign vascular neoplasm that is usually located on the face or neck.
  • Exceptionally, it has been described affecting the colon, with only two such cases described in the worldwide literature.
  • The aim here was to present a case of primary epithelioid hemangioma of the sigmoid colon with confirmation by immunohistochemical examination.
  • Neoplasia of the colon was clinically suspected and she underwent colonoscopy.
  • A biopsy collected during the examination suggested a diagnosis of neoplasia of vascular origin.
  • After surgical resection, histopathological examination of the resected specimen confirmed the diagnosis of epithelioid hemangioma of the colon, which was backed up by the immunohistochemical panel (factor VIII, Ki-67, CD-34).
  • Despite the rarity of neoplasia of vascular origin, this possibility should be considered in the differential diagnosis for colorectal tumors.
  • [MeSH-major] Angiolymphoid Hyperplasia with Eosinophilia / pathology. Colon / pathology. Hemangioma / pathology. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099166.001).
  • [ISSN] 1806-9460
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


33. Winter H, Lang RA, Spelsberg FW, Jauch KW, Hüttl TP: Laparoscopic colonoscopic rendezvous procedures for the treatment of polyps and early stage carcinomas of the colon. Int J Colorectal Dis; 2007 Nov;22(11):1377-81
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colonoscopic rendezvous procedures for the treatment of polyps and early stage carcinomas of the colon.
  • BACKGROUND AND AIMS: Endoscopic treatment of large or colonoscopically inaccessible polyps or early stage tumors in the colon holds the risk of incomplete resection and colonic perforation.
  • Aim of this study was to assess the feasibility and outcome of patients operated on by laparoendoscopic rendezvous procedures at the colon.
  • MATERIALS AND METHODS: The medical records of 38 patients (21 male, 17 female, median age 66 years [range 39-90]) undergoing rendezvous surgery at the colon were reviewed prospectively.
  • A benign lesion was confirmed histologically in 31 patients.
  • In five cases, histopathologic diagnosis revealed a malignancy necessitating colonic surgery.
  • CONCLUSION: Rendezvous procedures offer a safe, minimal-invasive therapeutic approach allowing the resection of benign sessile or colonoscopically inaccessible localized polyps and of early stage colon cancer.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / therapy. Colonic Polyps / therapy. Colonoscopy / methods. Laparoscopy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Length of Stay. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):340-8 [12626909.001]
  • [Cites] Am Surg. 1988 Feb;54(2):61-3 [3341645.001]
  • [Cites] J Am Coll Surg. 1994 Nov;179(5):513-7 [7952451.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Surg Endosc. 1997 Jun;11(6):643-4 [9171124.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] Surg Technol Int. 2003;11:97-101 [12931289.001]
  • [Cites] Dis Colon Rectum. 1994 Aug;37(8):775-6 [7519975.001]
  • [Cites] Ann Intern Med. 1993 Oct 15;119(8):836-43 [8379605.001]
  • [Cites] Surg Laparosc Endosc. 1995 Apr;5(2):137-8 [7773461.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Dis Colon Rectum. 2001 Jan;44(1):112-8 [11805571.001]
  • [Cites] Surg Laparosc Endosc. 1994 Oct;4(5):382-3 [8000642.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):746-8 [11357040.001]
  • [Cites] Arch Surg. 2005 Jul;140(7):692-7 [16027336.001]
  • [Cites] Mayo Clin Proc. 2000 Apr;75(4):344-8 [10761487.001]
  • [Cites] Surg Endosc. 1994 Nov;8(11):1352-3 [7831614.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1513-6 [14605571.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • [Cites] ANZ J Surg. 2003 Dec;73(12):988-95 [14632888.001]
  • (PMID = 17646999.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Grady WM: Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans; 2005 Aug;33(Pt 4):684-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic events in the colorectum and in colon cancer.
  • Colon cancers arise from benign neoplasms and evolve into adenocarcinomas through a stepwise histological progression sequence, proceeding from either adenomas or hyperplastic polyps/serrated adenomas.
  • Genetic alterations have been associated with specific steps in this polyp-adenocarcinoma sequence and are believed to drive the histological progression of colon cancer.
  • Recently, epigenetic alterations, which include CGI (CpG island) DNA methylation, have been shown to occur in colon polyps and colon cancer.
  • The aberrant methylation of genes appears to co-operate with the genetic alterations to drive the initiation and progression of colon polyps to colon cancer.
  • These hypermethylated genes are not only probable pathogenic events affecting colon-cancer formation, but also neoplasm-specific molecular events that may be useful as molecular markers for colon tumours.
  • Furthermore, aberrant DNA methylation of tumour-suppressor genes may occur secondary to a genetic predisposition or to a field-cancerization effect in the colon and may be useful as molecular markers for the risk of developing colon cancer.
  • [MeSH-major] Colon / physiology. Colonic Neoplasms / genetics. Epigenesis, Genetic / genetics. Rectum / physiology
  • [MeSH-minor] Colonic Polyps / genetics. Gene Silencing. Genetic Markers. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16042574.001).
  • [ISSN] 0300-5127
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 33
  •  go-up   go-down


35. Fumimoto Y, Tamagawa K, Ito T, Sawa Y, Nishida T: Localized giant inflammatory polyposis of the ileocecum associated with Crohn's disease: report of a case. Case Rep Gastroenterol; 2008;2(1):128-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although inflammatory polyposis is one of the common complications in patients with inflammatory bowel disease, it is rare that each poly grows up to more than 1.5 cm.
  • Barium enema and colonoscopy showed numerous worm-like polyps in the ascending colon which grew up to the hepatic flexure of the colon from the ileocecum, causing an obstruction of the ileocecal orifice.
  • Histological examination revealed inflammatory polyposis without neoplasm.
  • Generally, conservative treatment is indicated for localized giant inflammatory polyposis because this lesion is regarded as benign.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1999 Dec;50(6):869-71 [10570361.001]
  • [Cites] Am J Gastroenterol. 1992 Mar;87(3):379-81 [1539578.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):802-4 [3652893.001]
  • [Cites] Am J Surg Pathol. 1986 Jun;10(6):420-8 [3717497.001]
  • [Cites] Gastroenterology. 1978 Dec;75(6):1142-6 [710866.001]
  • [Cites] South Med J. 1981 Jul;74(7):850-5 [7256332.001]
  • [Cites] Br Med J. 1966 Jun 11;1(5501):1442-7 [5933046.001]
  • [Cites] Br J Radiol. 1978 Oct;51(610):782-7 [709018.001]
  • [Cites] Lancet. 1969 Sep 13;2(7620):555-9 [4185531.001]
  • (PMID = 21490852.001).
  • [ISSN] 1662-0631
  • [Journal-full-title] Case reports in gastroenterology
  • [ISO-abbreviation] Case Rep Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3075180
  • [Keywords] NOTNLM ; Crohn's disease / Ileus / Localized giant inflammatory polyposis
  •  go-up   go-down


36. Hu X, Tian DY, Cao L, Yu Y: Progression and prognosis of gastric stump cancer. J Surg Oncol; 2009 Nov 1;100(6):472-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to determine the clinicopathologic feature and the differences of surgical outcome between GSC after partial gastrectomy for benign diseases (GSC-B) and GSC after partial gastrectomy for malignant tumors (GSC-M).
  • No difference was found between patients with GSC-B and patients with GSC-M in terms of histologic type, tumor location, and distribution of tumor stage.
  • [MeSH-minor] Aged. Carcinoma / mortality. Carcinoma / pathology. Carcinoma / surgery. Case-Control Studies. Colon / pathology. Female. Gastrectomy / methods. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Pancreas / pathology. Prognosis. Retrospective Studies. Spleen / pathology. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Surg Oncol. 2009 Nov 1;100(6):523. Yi, Yu [corrected to Yu, Yi]
  • (PMID = 19697396.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Neri-Jiménez U: [Digestive tract malignant neoplasms in patients of No. 11 area IMSS in Nuevo Laredo, Tamaulipas.]. Rev Gastroenterol Mex; 2008;73(4):197-202

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neoplasias malignas del aparato digestivoen población derechohabiente del IMSS No. 11,Nuevo Laredo, Tamaulipas.
  • However,the profile of cancer mortality in developing countries still presents a clear upward pattern, and Mexico is not the exception, for the mortality rate due to malignant tumors has shown an increase recently, which constitutes a great challenge for health institutions.
  • Benign neoplasms and metastasis were excluded.
  • According to the Pathology report, 24.4% were diagnosed with hepatic cancer,23.03% were colon and rectum cancer, 20.00%were stomach cancer, 13.33% with pancreatic cancer,and 7.27% were cancer of esophagus.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Humans. Male. Mexico / epidemiology. Middle Aged. Neoplasm Metastasis / pathology. Sex Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666268.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


38. Ciancio G, Vaidya A, Shirodkar S, Manoharan M, Hakky T, Soloway M: En bloc mobilization of the pancreas and spleen to facilitate resection of large tumors, primarily renal and adrenal, in the left upper quadrant of the abdomen: techniques derived from multivisceral transplantation. Eur Urol; 2009 May;55(5):1106-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] En bloc mobilization of the pancreas and spleen to facilitate resection of large tumors, primarily renal and adrenal, in the left upper quadrant of the abdomen: techniques derived from multivisceral transplantation.
  • Pathology included malignant and benign lesions, including renal cell carcinoma (RCC) with or without inferior vena cava (IVC) involvement, adrenal tumors, retrocrural lymphadenopathy from testicular cancer, and transitional cell carcinoma of the renal pelvis.
  • SURGICAL PROCEDURE: An extended subcostal transabdominal approach was used to resect large tumors in the left upper abdomen.
  • This approach offers significant advantages over conventional approaches, including a flank, thoracoabdominal, or midline transabdominal incision with reflection of the descending colon.
  • [MeSH-minor] Abdominal Cavity / surgery. Adrenalectomy / methods. Adult. Aged. Aged, 80 and over. Blood Loss, Surgical. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Monitoring, Intraoperative / methods. Neoplasm Invasiveness / pathology. Neoplasm Staging. Nephrectomy / methods. Pancreas / anatomy & histology. Postoperative Complications / prevention & control. Retrospective Studies. Risk Assessment. Spleen / anatomy & histology. Stomach / anatomy & histology. Treatment Outcome. Tumor Burden. Vena Cava, Inferior. Young Adult


39. Bonekamp D, Jacene H, Bartelt D, Aygun N: Conversion of FDG PET activity of fibrous dysplasia of the skull late in life mimicking metastatic disease. Clin Nucl Med; 2008 Dec;33(12):909-11
Genetic Alliance. consumer health - Fibrous Dysplasia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibrous dysplasia (FD) accounts for 7% of benign bone tumors.
  • It is a developmental disorder of unclear etiology.
  • We describe a case of FD of the skull in a patient of advanced age (69 years) with recent diagnosis of colon cancer, which changed its FDG activity and CT appearance within 10 months of follow-up.
  • [MeSH-major] Fibrous Dysplasia of Bone / radionuclide imaging. Fluorodeoxyglucose F18. Molecular Mimicry. Neoplasm Metastasis / pathology. Positron-Emission Tomography. Skull / pathology. Skull / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033807.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


40. Øgreid D, Hamre E: Stool DNA analysis detects premorphological colorectal neoplasia: a case report. Eur J Gastroenterol Hepatol; 2007 Aug;19(8):725-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stool DNA analysis detects premorphological colorectal neoplasia: a case report.
  • Colorectal cancers usually develop from benign adenomas in a lengthy period of 5-10 years.
  • This case report shows that the use of genetic markers in stool testing has the potential to detect colon cancer in its very early stages when treatment is simple and often successful.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. DNA, Neoplasm / analysis. Feces / chemistry. Precancerous Conditions / diagnosis
  • [MeSH-minor] Colonic Polyps / diagnosis. Genetic Markers. Humans. Male. Middle Aged. Mutation. Neoplastic Syndromes, Hereditary / diagnosis. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625445.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


41. Colović R, Grubor N, Radak V, Micev M, Stojković M, Colović N: [Aggressive intraabdominal fibromatosis]. Vojnosanit Pregl; 2006 Sep;63(9):839-42
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intraabdominal or mesenteric fibromatosis is a rare benign nonmetastatic neoplasm that appears as a sporadic lesion or in patients with familiar polyposis.
  • CASE REPORT: We presented a 22-year-old woman in whom an aggressive intraabdominal fibromatosis had appeared during the first pregnancy as a well circumscribed ovoid tumor, involving the terminal ileum, the caecum, the ascending colon, the right kidney, the ureter, and the right common iliac artery.
  • The tumor was excised with right colectomy, nephroureterectomy and resection of the involved artery using arterial reconstruction with graft interposition.
  • Two years after the surgery the patient developed an inoperable tumor recurrency with a fatal outcome.
  • CONCLUSION: In spite of a successful surgical excision during the original surgery intraabdominal or mesenteric fibromatosis might have an aggressive evolution leading to an inoperable tumor recurrency and a fatal outcome.
  • [MeSH-major] Fibromatosis, Abdominal / pathology. Fibromatosis, Aggressive / pathology. Neoplasm Recurrence, Local. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Aggressive Fibromatosis.
  • Genetic Alliance. consumer health - Fibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17039898.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


42. Tsafrir D, Bacolod M, Selvanayagam Z, Tsafrir I, Shia J, Zeng Z, Liu H, Krier C, Stengel RF, Barany F, Gerald WL, Paty PB, Domany E, Notterman DA: Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res; 2006 Feb 15;66(4):2129-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several studies have verified the existence of multiple chromosomal abnormalities in colon cancer.
  • In this work, three types of array-generated data (expression, single nucleotide polymorphism, and comparative genomic hybridization) were collected from a large set of colon cancer patients at various stages of the disease.
  • Indeed, particular chromosomal regions are frequently gained and overexpressed (e.g., 7p, 8q, 13q, and 20q) or lost and underexpressed (e.g., 1p, 4, 5q, 8p, 14q, 15q, and 18) in primary colon tumors, making it likely that these changes favor tumorigenicity.
  • Furthermore, we show that these aberrations are absent in normal colon mucosa, appear in benign adenomas (albeit only in a small fraction of the samples), become more frequent as disease advances, and are found in the majority of metastatic samples.
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Chromosomes, Human, Pair 20 / genetics. DNA, Neoplasm / genetics. Gene Dosage. Gene Expression Profiling. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16489013.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA65930
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


43. Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, De Luca A, Jones B, Balogh G, Russo J, Mailo D, Palaia R, D'Aiuto G, Botti G, Perrone F, Salomon DS, Normanno N: Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res; 2006 Sep 1;12(17):5158-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of cripto-1 as a novel serologic marker for breast and colon cancer.
  • PURPOSE: Human Cripto-1 (CR-1), a cell membrane glycosylphosphatidylinositol-anchored glycoprotein that can also be cleaved from the membrane, is expressed at high levels in several different types of human tumors.
  • We evaluated whether CR-1 is present in the plasma of patients with breast and colon cancer, and if it can represent a new biomarker for these malignancies.
  • EXPERIMENTAL DESIGN: We determined CR-1 plasma levels using a sandwich-type ELISA in 21 healthy volunteers, 54 patients with breast cancer, 33 patients with colon carcinoma, and 21 patients with benign breast lesions.
  • A statistically significant increase in the levels of plasma CR-1 was found in patients with colon carcinoma (4.68+/-3.5 ng/mL) and in patients with breast carcinoma (2.97+/-1.48 ng/mL; P<0.001).
  • Although moderate levels of plasma CR-1 were found in women with benign lesions of the breast (1.7+/-0.99 ng/mL), these levels were significantly lower than in patients with breast cancer (P<0.001).
  • Finally, immunohistochemical analysis and real-time reverse transcription-PCR confirmed strong positivity for CR-1 in colon and/or breast tumor tissues.
  • CONCLUSION: This study suggests that plasma CR-1 might represent a novel biomarker for the detection of breast and colon carcinomas.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Colonic Neoplasms / blood. Colonic Neoplasms / diagnosis. Epidermal Growth Factor / blood. Membrane Glycoproteins / blood. Neoplasm Proteins / blood
  • [MeSH-minor] Animals. Enzyme-Linked Immunosorbent Assay / methods. Female. GPI-Linked Proteins. Humans. Immunohistochemistry / methods. Intercellular Signaling Peptides and Proteins. Male. Mice. Mice, Transgenic. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951234.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TDGF1 protein, human; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


44. Stojanovic MP, Radojkovic M, Jeremic LM, Zlatic AV, Stanojevic GZ, Jovanovic MA, Kostov MS, Katic VP: Malignant schwannoma of the pancreas involving transversal colon treated with en-bloc resection. World J Gastroenterol; 2010 Jan 7;16(1):119-22
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant schwannoma of the pancreas involving transversal colon treated with en-bloc resection.
  • Pancreatic schwannoma is a very uncommon tumor of the pancreas, with only 27 cases reported.
  • Most pancreatic schwannomas are benign, with only four malignant tumors reported.
  • We describe a case of giant malignant schwannoma of the pancreatic body and tail, which involved the transverse colon.
  • The tumor was treated successfully with en bloc distal splenopancreatectomy and colon resection.
  • This is believed to be the first reported radical operation for malignant schwannoma of the pancreatic body, with infiltration of the transverse colon, with excellent long-term results.
  • In the case of the benign tumors, local excision is adequate, but in the case of malignant schwannoma, oncological standards must be fulfilled.
  • [MeSH-major] Colectomy. Colon / surgery. Neurilemmoma / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Biopsy. Female. Humans. Lymph Node Excision. Neoplasm Invasiveness. Splenectomy. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1999;29(10):1093-7 [10554337.001]
  • [Cites] Ann Diagn Pathol. 2008 Aug;12(4):296-300 [18621000.001]
  • [Cites] J Neurosurg. 2003 Oct;99(4):685-92 [14567604.001]
  • [Cites] Ann Diagn Pathol. 2003 Oct;7(5):285-91 [14571430.001]
  • [Cites] Surg Today. 2004;34(6):550-3 [15170556.001]
  • [Cites] Acta Chir Scand. 1982;148(8):697-8 [7170905.001]
  • [Cites] J Surg Oncol. 1987 Sep;36(1):21-5 [3626558.001]
  • [Cites] Gastroenterology. 1989 Dec;97(6):1550-1 [2511055.001]
  • [Cites] Semin Roentgenol. 1990 Apr;25(2):127-9 [2112269.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):675 [1503050.001]
  • [Cites] AJR Am J Roentgenol. 1992 Nov;159(5):1023-6 [1414767.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jul;165(1):232 [7785620.001]
  • [Cites] Pancreas. 1997 Jul;15(1):99-105 [9211499.001]
  • [Cites] Cytopathology. 1999 Jun;10(3):186-94 [10390067.001]
  • [Cites] JOP. 2004 Nov;5(6):520-6 [15536295.001]
  • [Cites] Clin Imaging. 2005 Nov-Dec;29(6):434-6 [16274899.001]
  • [Cites] J Comput Assist Tomogr. 2000 Jul-Aug;24(4):622-7 [10966199.001]
  • (PMID = 20039458.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2799907
  •  go-up   go-down


45. Bui MM, Draper NL, Dessureault S, Nasir NA, Cooper H, Nasir A, Coppola D: Colonic angiolymphoid hyperplasia with eosinophilia masquerading as malignancy: a case report and review of the literature. Clin Colorectal Cancer; 2010 Jul;9(3):179-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic angiolymphoid hyperplasia with eosinophilia masquerading as malignancy: a case report and review of the literature.
  • Angiolymphoid hyperplasia with eosinophilia (AHE) of the colon is a rare entity.
  • Here, we report a third case that presented as a transverse colonic mass mimicking cancer both clinically and radiologically.
  • Whether AHE is a reactive process or a neoplastic process (either a benign vascular neoplasm or a T-cell lymphoproliferative disorder) is still under debate.
  • However, it is important to recognize this entity as a cause of colonic mass to avoid a misdiagnosis of malignancy.
  • [MeSH-major] Angiolymphoid Hyperplasia with Eosinophilia / pathology. Colonic Diseases / pathology. Colonic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20643624.001).
  • [ISSN] 1938-0674
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


46. Mendes RA, Carvalho JF, Waal Iv: An overview on the expression of cyclooxygenase-2 in tumors of the head and neck. Oral Oncol; 2009 Oct;45(10):e124-8
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview on the expression of cyclooxygenase-2 in tumors of the head and neck.
  • Cyclooxygenase-2 (COX-2) levels are increased in various tumors, particularly those involving the esophagus, stomach, breast, pancreas, lung, colon, skin, urinary bladder, prostate and head and neck.
  • Thus, the literature shows increasing evidence that overexpression of the COX-2 plays an important role in tumor growth and spread of tumors by interfering with different biological processes such as cell proliferation, cellular adhesion, immune surveillance, apoptosis, and angiogenesis.
  • Furthermore, the expression of COX-2 might shed some light over the physiopathology and clinical behavior of tumors of the head and neck, including benign odontogenic neoplasms of the jaws with an aggressive behavior, such as keratocystic odontogenic tumors (KCOT).
  • Ultimately, the research of molecular markers associated with the biological behavior of tumors will help to understand the underlying molecular mechanisms and to predict the clinical outcome, leading to the development of new therapeutic applications, such as molecular-targeted treatment and patient tailored therapy.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Head and Neck Neoplasms / metabolism. Neoplasm Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19457709.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Prostaglandins; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


47. Achiam MP, Andersen LP, Klein M, Løgager V, Chabanova E, Thomsen HS, Rosenberg J: Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study. Eur J Radiol; 2010 Jun;74(3):e45-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study.
  • BACKGROUND: Colorectal cancer will present itself as a bowel obstruction in 16-23% of all cases.
  • However, not all obstructing tumors are malignant and the differentiation between a benign and a malignant tumor can be difficult.
  • The purpose of our study was to determine whether fast dynamic gadolinium-enhanced MR imaging combined with MR colonography could be used to differentiate a benign from a malignant obstructing colon tumor.
  • METHODS: Patients with benign colon tumor stenosis, based on diverticulitis, were asked to participate in the study.
  • Two blinded observers analyzed the tumors on MR by placing a region of interest in the tumor and a series of parameters were evaluated, e.g. wash-in, wash-out and time-to-peak.
  • The wash-in and wash-out rates were significantly different between the benign and malignant tumors, and a clear distinction between benign and malignant disease was therefore possible by looking only at the MR data.
  • Furthermore, MR colography evaluating the rest of the colon past the stenosis was possible with all patients.
  • CONCLUSION: The results showed the feasibility of using fast dynamic gadolinium-enhanced MR imaging to differentiate between benign and malignant colonic tumors.
  • With a high intra-class correlation and significant differences found on independent segments of the tumor, the method appears to be reproducible.
  • Furthermore, the potential is big in performing a full preoperative colon evaluation even in patients with obstructing cancer.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Diverticulitis / diagnosis. Diverticulitis / etiology. Image Enhancement / methods. Magnetic Resonance Imaging / methods. Meglumine. Organometallic Compounds

  • MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19419830.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00114829
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadoterate meglumine; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


48. Stübinger SH, van der Horst Ch, Braun PM: [Pelvic tumors in the eyes of urologists]. Ther Umsch; 2007 Jul;64(7):395-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic tumors in the eyes of urologists].
  • [Transliterated title] Raumforderungen im kleinen Becken aus Sicht des Urologen.
  • Pelvic tumors originating from outside the urinary tract commonly invade the urogenital organs by direct extension mainly because of the close relationships between the pelvic organs.
  • Benign tumors such as endometrial myoma, ovarian cyst and adenoma of the colon might lead to the development of urogenital symptoms.
  • This is also the case with malignant tumors of the uterus, ovaries, cervix and colon where infiltration of the urogenital organs might be noted.
  • These are the symptoms that lead to the diagnosis of the primary tumor.
  • It has to be kept in mind that urogenital tumors with such symptoms have to be included in the differential diagnosis.
  • The possibility of eradicating the tumor is then to be discussed after relieving the obstruction.
  • [MeSH-minor] Cystectomy. Cystoscopy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Prostatectomy. Quality of Life. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948757.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


49. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol; 2009;20(3):149-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.
  • It is highly expressed in carcinomas of the pancreas, stomach, colon, rectum, kidneys, uterine cervix, lung, and ovary.
  • Of the 60 FVPC, 23 tumors (38%) were positive for IMP3, with 13 of these (22%) showing very strong staining (3+).
  • Of the 32 FC, 22 tumors (69%) were positive, with seven (22%) showing very strong staining (3+).
  • No significant correlation was found between pathologic tumor characteristics and IMP3 expression in differentiated follicular pattern thyroid carcinoma.
  • With 100% specificity and 69% sensitivity for FC as compared to FA and 100% specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Biomarkers, Tumor / analysis. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19449140.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


50. Nahal A, Meterissian S: Lipoleiomyosarcoma of the rectosigmoid colon: a unique site for a rare variant of liposarcoma. Am J Clin Oncol; 2009 Aug;32(4):353-5
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipoleiomyosarcoma of the rectosigmoid colon: a unique site for a rare variant of liposarcoma.
  • OBJECTIVES: Soft tissue tumors with dual adipocytic and smooth muscle differentiation are generally rare with most being benign.
  • [MeSH-major] Leiomyosarcoma / pathology. Liposarcoma / pathology. Neoplasm Invasiveness / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Colectomy / methods. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Laparotomy / methods. Middle Aged. Neoplasm Staging. Pelvic Pain / diagnosis. Pelvic Pain / etiology. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19363435.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


51. Singhi AD, Montgomery EA: Colorectal granular cell tumor: a clinicopathologic study of 26 cases. Am J Surg Pathol; 2010 Aug;34(8):1186-92
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal granular cell tumor: a clinicopathologic study of 26 cases.
  • Granular cell tumor (GCT) is commonly located in the subcutaneous tissue and oral cavity, and uncommon in the gastrointestinal tract, in which the majority arises in the esophagus with over-representation in African Americans (AA).
  • The majority of colorectal GCT involved the right colon (19/26, 73%) ranging in size from 0.2 to 1.8 cm (mean 0.6 cm).
  • Most neoplasms were encountered on routine colonoscopy (14/24, 64%), however 3 patients presented with hematochezia, 3 with changing bowel habits, 2 with Crohn disease, 1 with diverticular disease, and 1 with appendicitis.
  • Of the 20 cases available for histologic review, the tumors were noted to either be infiltrative (12/20, 60%) or marginated (8/20, 40%) involving either the mucosa (7/20, 35%), submucosa (10/20, 50%), or both (3/20, 15%).
  • Although infrequently found in the colorectum, colorectal GCT typically presents incidentally on routine colonoscopy and involves the right colon; it is not over-represented in AA patients.
  • Although GCTs were benign tumors in this series, if incompletely excised regrowth of the lesion may occur and therefore, follow-up may be warranted.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy. Colectomy. Colonoscopy. Female. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. S100 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661017.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


52. Seidman JD, Kumar D, Cosin JA, Winter WE 3rd, Cargill C, Boice CR: Carcinomas of the female genital tract occurring after pelvic irradiation: a report of 15 cases. Int J Gynecol Pathol; 2006 Jul;25(3):293-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five of these patients had HPV-related tumors both pre- and post- irradiation.
  • Ten were irradiated for cervical cancer, one for endometrial carcinoma, one for vulvar carcinoma, one for colon cancer and 2 for benign conditions.
  • Although the evidence for a causative role is circumstantial, these tumors appear to have a similar latent period as postradiation sarcomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Risk Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810069.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol; 2005 Apr;192(4):1214-21; discussion 1221-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased risk includes women with at least 1 affected first-degree relative with ovarian cancer; a personal history of breast, ovarian, or colon cancer; > or =1 affected first- and second-degree relatives with breast and or ovarian cancer; inheritance of a breast cancer mutation from an affected family member, or membership within a recognized cancer syndrome.
  • A total of 98 women with persistent adnexal masses were identified, and 49 invasive surgical procedures were performed that diagnosed 37 benign ovarian tumors and 12 gynecologic malignancies.
  • [MeSH-minor] Adult. Age Distribution. Aged. Cohort Studies. Female. Humans. Immunohistochemistry. Incidence. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Ultrasonography, Doppler, Color

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846205.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA83639; United States / NCI NIH HHS / CA / R01 CA01015; United States / NCI NIH HHS / CA / R01 CA82562; United States / NCI NIH HHS / CA / R01 CA89503; United States / NCI NIH HHS / CA / UO1CA85133
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


54. Belinsky GS, Claffey KP, Nambiar PR, Guda K, Rosenberg DW: Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line. Mol Carcinog; 2005 Jun;43(2):65-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line.
  • The organo-specific carcinogen, azoxymethane (AOM), produces colon tumors in mice that share many pathological features with sporadic human colorectal cancer (CRC).
  • To assess the role of the microenvironment in preventing the invasive phenotype, multiple benign in situ adenocarcinomas were harvested from AOM-treated mice and cultured in vitro.
  • However, tumor cell growth was extremely limiting under standard culturing conditions.
  • Thus, we injected tumor cells directly into nude mice and performed two serial transplants, and successfully explanted a rapidly growing epithelial tumor cell line (AJ02nm(0)).
  • When injected subcutaneously (sc) into nude mice, AJ02nm(0) cells formed well-differentiated adenocarcinomas with minimal tumor invasive capacity.
  • AJ02nm-VEGF cells produced rapidly growing tumors in nude mice that exhibited extensive pseudo-epithelial ductal architecture and supporting vasculature, but without increased invasive potential compared to controls.
  • The established murine colon epithelial cell line provides a useful experimental model to further elaborate genetic and epigenetic factors that may promote or inhibit colon tumorigenesis and metastasis.
  • [MeSH-major] Colonic Neoplasms / blood supply. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Animals. Antigens, CD31 / analysis. Apoptosis. Cell Division. Cell Line, Tumor. Colorectal Neoplasms / blood supply. Colorectal Neoplasms / pathology. Karyotyping. Male. Mice. Mice, Inbred A. Mice, Nude. Neoplasm Transplantation. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15768385.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 81428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


55. Alderete J, Novais EN, Dozois EJ, Rose PS, Sim FF: Morbidity and functional status of patients with pelvic neurogenic tumors after wide excision. Clin Orthop Relat Res; 2010 Nov;468(11):2948-53
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morbidity and functional status of patients with pelvic neurogenic tumors after wide excision.
  • BACKGROUND: We previously reported that over the last 10 years our practice has evolved in the treatment of neurogenic tumors of the pelvis to include a multispecialty team of surgeons, a factor that might decrease morbidity and improve recurrence, survival, and function.
  • QUESTIONS/PURPOSES: Therefore, we (1) assessed the morbidity associated with surgical excision in patients with neurogenic tumors of the pelvis;.
  • METHODS: We reviewed the records of all 38 patients who had surgery for a pelvic plexus tumor between 1994 and 2005.
  • Twelve patients had a malignant tumor.
  • We recorded demographic data, postoperative complications, tumor-specific recurrence, and determined survival.
  • Patients with benign tumors had a mean MSTS score of 94%, while survivors of malignant disease had a mean of 57%.
  • For malignant tumors, the 5-year rate of local recurrence was 40%, the estimated 5-year rate of metastasis was 67% and 5-year survival rate was 50%.
  • CONCLUSION: Using a team approach, surgical excision provided high functional scores for patients with benign disease with a low rate of complications.
  • In patients with malignant tumors, intentional wide resection is associated with higher morbidity but yields acceptable functional scores.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Minnesota. Neoplasm Recurrence, Local. Recovery of Function. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2001 Sep;(390):190-205 [11550866.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):1010-6 [19194756.001]
  • [Cites] Neurology. 2003 Sep 9;61(5):696-8 [12963767.001]
  • [Cites] Neurosurg Clin N Am. 2004 Apr;15(2):177-92 [15177317.001]
  • [Cites] Cancer. 1973 Jan;31(1):184-90 [4683036.001]
  • [Cites] Dis Colon Rectum. 1981 Oct;24(7):501-6 [7297357.001]
  • [Cites] Mayo Clin Proc. 1983 Oct;58(10):640-7 [6621104.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):644-52 [2996861.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] J Neurosurg. 1986 Sep;65(3):286-95 [3734878.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):601-12 [3559651.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1253-65 [2119249.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):23-30 [10469433.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):81-7 [16788949.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1065-74 [16881077.001]
  • [Cites] Neurosurg Focus. 2007;22(6):E10 [17613201.001]
  • [Cites] Neurosurg Focus. 2007;22(6):E13 [17613204.001]
  • [Cites] Surgery. 2003 May;133(5):473-8 [12773974.001]
  • (PMID = 20668971.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2947704
  •  go-up   go-down


56. Belizon A, Balik E, Horst PK, Shantha Kumara HM, Nasar A, Whelan RL: Platelet-derived growth factor (subtype BB) is elevated in patients with colorectal carcinoma. Dis Colon Rectum; 2009 Jun;52(6):1166-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Platelet-derived growth factor-BB plays a role in the development of vascular and lymphatic vessels in tumors.
  • Preoperative colorectal cancer platelet-derived growth factor-BB levels were higher (1,771.1 pg/ml; confidence intervals, 1,429-2,065) than in the benign neoplasm group (1083 pg/ml; confidence intervals, 933-1,192, P < 0.001).
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Chi-Square Distribution. Enzyme-Linked Immunosorbent Assay. Female. Humans. Logistic Models. Male. Proto-Oncogene Proteins c-sis. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581863.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / platelet-derived growth factor BB
  •  go-up   go-down


57. Lee JH, Ross WA, Davila R, Chang G, Lin E, Dekovich A, Davila M: Self-expandable metal stents (SEMS) can serve as a bridge to surgery or as a definitive therapy in patients with an advanced stage of cancer: clinical experience of a tertiary cancer center. Dig Dis Sci; 2010 Dec;55(12):3530-6
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Self-expandable metal stents (SEMS) can be used to relieve benign and malignant colorectal obstruction.
  • The locations of the obstruction were as follows: two in the ascending colon, one in the hepatic flexure, three in the transverse colon, two in the splenic flexure, two in the descending colon, 26 in the sigmoid colon, and ten in the rectum.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colon, Sigmoid / pathology. Colorectal Neoplasms / complications. Colorectal Neoplasms / pathology. Constriction, Pathologic. Female. Fluoroscopy. Foreign-Body Migration / epidemiology. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prosthesis Design. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20721627.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Jung SH, Paik CN, Jung JH, Lee KM, Chung WC, Yang JM: Simultaneous Colonic Obstruction and Hydroureteronephrosis due to Mesenteric Fibromatosis. Gut Liver; 2009 Sep;3(3):215-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous Colonic Obstruction and Hydroureteronephrosis due to Mesenteric Fibromatosis.
  • Mesenteric fibromatosis (MF) is a rare benign mesenchymal lesion that can occur throughout the gastrointestinal tract, especially small bowel.
  • Its biological behavior is intermediate between benign fibrous tissue proliferation and malignant fibrosarcoma.
  • In previously reported cases of MF, we could find colonic obstruction or ureter obstruction, but simultaneous involvement of colon and ureter was not able to be seen.
  • We described a patient that presented with colonic obstruction and hydroureteronephrosis due to MF at sigmoid colon which mimicked submucosal tumor such as gastrointestinal tumor.
  • This case resulted in a positive positron emission tomography scan suggesting malignant neoplasm, but beta-catenin positivity on immunohistochemical staining separated MF from gastrointestinal stromal tumor and sclerosing mesenteritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2007 Dec 7;13(45):5985-8 [18023087.001]
  • [Cites] Dis Colon Rectum. 2007 Jun;50(6):924-6 [17205200.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5226-8 [16127758.001]
  • [Cites] Histopathology. 1994 Nov;25(5):469-73 [7532614.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):947-57 [10895817.001]
  • [Cites] AJR Am J Roentgenol. 1991 Aug;157(2):275-9 [1853806.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):335-41 [2321698.001]
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):93-8 [14750246.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1296-301 [12360044.001]
  • [Cites] AJR Am J Roentgenol. 1991 Mar;156(3):539-42 [1899752.001]
  • (PMID = 20431749.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2852704
  • [Keywords] NOTNLM ; Colonic obstruction / Hydroureteronephrosis / Mesenteric fibromatosis
  •  go-up   go-down


59. Ducreux M, Dromain C: [Non-invasive imaging tools in colorectal cancer]. Rev Prat; 2010 Oct 20;60(8):1071-3
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Coloscanner is a new radiologic tool to determine if abnormalities of colon and especially neoplasms are present.
  • In colorectal neoplasm, it is now considered as essential for the diagnosis of unexplained raise of CEA levels, differential diagnosis between benign and malignant disease (especially for suspected local recurrence of rectal cancer), or preoperative staging in case of complex surgical strategies.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21197735.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


60. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR: Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol; 2010;8:147
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent data provide significant evidence to support the hypothesis that there are sub-populations of cells within solid tumors that have an increased tumor initiating potential relative to the total tumor population.
  • CD133, a cell surface marker expressed on primitive cells of neural, hematopoietic, endothelial and epithelial lineages has been identified as a marker for tumor initiating cells in solid tumors of the brain, colon, pancreas, ovary and endometrium.
  • Our objectives were to assess the relative level of CD133 expressing cells in primary human endometrial tumors, confirm their tumorigenic potential, and determine whether CD133 expression was epigenetically modified.
  • METHODS: We assessed CD133 expression in primary human endometrial tumors by flow cytometry and analyzed the relative tumorigenicity of CD133+ and CD133- cells in an in vivo NOD/SCID mouse model.
  • We further examined CD133 promoter methylation and expression in normal endometrium and malignant tumors.
  • In addition, we confirmed the tumor initiating potential of CD133+ and CD133- cell fractions in NOD/SCID mice.
  • Interestingly, the percentage of CD133+ cells in human endometrial tumor xenografts, as evidenced by immunofluorescence, increased with serial transplantation although this trend was not consistently detected by flow cytometry.
  • To support this finding, we demonstrated that regions of the CD133 promoter were hypomethylated in malignant endometrial tissue relative to benign control endometrial tissue.
  • Lastly, we determined that methylation of the CD133 promoter decreases over serial transplantation of an endometrial tumor xenograft.
  • [MeSH-minor] Animals. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 Oct;18(10):1037-46 [18679414.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8094-103 [18829568.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cancer Lett. 2009 Jun 28;279(1):13-21 [19232461.001]
  • [Cites] Biol Reprod. 2009 Jun;80(6):1136-45 [19228591.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):2235-7 [19528487.001]
  • [Cites] Clin Cancer Res. 2009 Jul 1;15(13):4299-311 [19509143.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8241-8 [19843861.001]
  • [Cites] Stem Cells. 2009 Oct;27(10):2405-13 [19658191.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] J Biochem. 2010 Sep;148(3):273-80 [20551139.001]
  • [Cites] Hum Pathol. 2010 Nov;41(11):1516-29 [20800872.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Endocr Relat Cancer. 2000 Dec;7(4):227-42 [11174845.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Biol Reprod. 2004 Jun;70(6):1738-50 [14766732.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Biol Reprod. 1989 Mar;40(3):681-90 [2758097.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1529-38 [16456137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Hum Reprod. 2007 Jan;22(1):45-51 [16923745.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1214-23 [17283036.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):479-85 [17762575.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):242-9 [18256549.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14 [17868344.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] J Mol Med (Berl). 2008 Sep;86(9):1025-32 [18535813.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):209-18 [18836486.001]
  • (PMID = 21122138.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC3027593
  •  go-up   go-down


61. Stojadinovic A, Peoples GE, Libutti SK, Henry LR, Eberhardt J, Howard RS, Gur D, Elster EA, Nissan A: Development of a clinical decision model for thyroid nodules. BMC Surg; 2009;9:12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four to seven percent of the United States adult population (10-18 million people) has a palpable thyroid nodule, however the majority (>95%) of thyroid nodules are benign.
  • While, fine needle aspiration remains the most cost effective and accurate diagnostic tool for thyroid nodules in current practice, over 20% of patients undergoing FNA of a thyroid nodule have indeterminate cytology (follicular neoplasm) with associated malignancy risk prevalence of 20-30%.
  • Given that the majority (70-80%) of these patients have benign surgical pathology, thyroidectomy in these patients is conducted principally with diagnostic intent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Oct 18;92(20):1657-66 [11036111.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3686-96 [15897565.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):4924-7 [12414851.001]
  • [Cites] Am Fam Physician. 2003 Feb 1;67(3):559-66 [12588078.001]
  • [Cites] Endocr Pract. 2004 May-Jun;10(3):234-41 [15310542.001]
  • [Cites] Ann Thorac Surg. 1989 Oct;48(4):556-9 [2679466.001]
  • [Cites] Clin Pharmacokinet. 1990 May;18(5):409-18 [2335046.001]
  • [Cites] Am J Med. 1992 Oct;93(4):359-62 [1415298.001]
  • [Cites] Ann Thorac Surg. 1995 Jun;59(6):1611-2 [7771861.001]
  • [Cites] Stat Med. 1995 May 15-30;14(9-10):971-86 [7569514.001]
  • [Cites] Thyroid. 1998 May;8(5):377-83 [9623727.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2015-24 [15657649.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):152-60 [15827796.001]
  • [Cites] Breast Cancer. 2005;12(3):203-10 [16110290.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1792-8 [16452240.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] AMIA Annu Symp Proc. 2005;:345-9 [16779059.001]
  • [Cites] Crit Care. 2006;10(3):R94 [16813658.001]
  • [Cites] Radiology. 2006 Sep;240(3):666-73 [16926323.001]
  • [Cites] J Natl Cancer Inst Monogr. 2006;(36):30-6 [17032892.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):239-47 [17024553.001]
  • [Cites] Anaesth Intensive Care. 2008 Jan;36(1):38-45 [18326130.001]
  • [Cites] Acad Emerg Med. 2008 May;15(5):466-75 [18439203.001]
  • [Cites] Ann Surg. 2008 May;247(5):843-53 [18438123.001]
  • [Cites] Cancer Lett. 2008 Jun 18;264(2):163-71 [18384937.001]
  • [Cites] Ren Fail. 2008;30(4):345-52 [18569905.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Jul;139(1):21-6 [18585556.001]
  • [Cites] Phys Rev Lett. 2008 Jun 27;100(25):258701 [18643711.001]
  • [Cites] Ophthalmology. 2008 Sep;115(9):1598-607 [18342942.001]
  • [Cites] Head Neck. 2001 Apr;23(4):305-10 [11400232.001]
  • (PMID = 19664278.001).
  • [ISSN] 1471-2482
  • [Journal-full-title] BMC surgery
  • [ISO-abbreviation] BMC Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Validation Studies
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2731077
  •  go-up   go-down


62. Costa G, Tomassini F, Tierno SM, Venturini L, Frezza B, Cancrini G, Mero A, Lepre L: [Emergency colonic surgery: analysis of risk factors predicting morbidity and mortality]. Chir Ital; 2009 Sep-Dec;61(5-6):565-71
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Emergency colonic surgery: analysis of risk factors predicting morbidity and mortality].
  • [Transliterated title] Chirurgia del colon in urgenza: analisi dei fattori di rischio di morbilità e mortalità.
  • The aim of the present study was to identify risk factors for morbidity and mortality in patients submitted to emergency colonic surgery.
  • Between 1997 and 2008 157 patients, 106 of whom affected by colon cancer (67.5%) and 51 by benign disease (32.5%), were treated.
  • Among patients affected by cancer the mortality rate was 15% (16 patients) and the morbidity rate 23.6% (25 patients), while among the patients with benign disease the mortality rate was 7.8% (4 patients) and the morbidity rate 9.8% (5 patients).
  • Emergency surgery for both neoplastic and benign colonic disease is still associated with an increased risk of death.
  • [MeSH-major] Colectomy / adverse effects. Colectomy / methods. Colonic Diseases / mortality. Colonic Diseases / surgery. Emergency Treatment
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Analysis of Variance. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Risk Assessment. Risk Factors

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20380259.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


63. Togashi K, Shimura K, Konishi F, Miyakura Y, Koinuma K, Horie H, Yasuda Y: Prospective observation of small adenomas in patients after colorectal cancer surgery through magnification chromocolonoscopy. Dis Colon Rectum; 2008 Feb;51(2):196-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign adenomas of 6 mm or less in size, diagnosed based on both nonmagnified and magnified observation, were left unresected with a maximum of three polyps per patient.
  • [MeSH-major] Adenoma / diagnosis. Colonic Polyps / surgery. Colonoscopy / methods. Digestive System Surgical Procedures / methods. Neoplasms, Second Primary / diagnosis. Postoperative Care / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Reoperation


64. Croce MV, Isla-Larrain M, Remes-Lenicov F, Colussi AG, Lacunza E, Kim KC, Gendler SJ, Segal-Eiras A: MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue. Histol Histopathol; 2006 08;21(8):849-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We studied 163 breast and 89 colorectal cancer specimens, 10 breast and 14 colorectal benign conditions, and 12 breast and 20 colorectal normal samples.
  • From each tumor sample, subcellular fractions were obtained and analyzed by SDS-PAGE and WB.
  • Seven out of ten (70%) benign breast specimens were positive with CT33 while all samples stained with CT2; in normal breast sample tissues, all were positive with both Abs.
  • In colorectal cancer samples, both antibodies stained 47/89 (53%) samples; CT2 reacted in 13/14 (93%) of benign samples while CT33 showed a positive reaction in 9/14 (64%) of benign specimens.
  • [MeSH-minor] Antibodies, Neoplasm / immunology. Antibodies, Neoplasm / metabolism. Biomarkers, Tumor. Breast / anatomy & histology. Breast / metabolism. Breast / pathology. Cell Fractionation. Colon / anatomy & histology. Colon / metabolism. Colon / pathology. Humans. Immunoenzyme Techniques. Rectum / anatomy & histology. Rectum / metabolism. Rectum / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691537.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / MUC-1 monoclonal antibody; 0 / Mucin-1; 0 / Organic Cation Transport Proteins; 0 / SLC22A16 protein, human
  •  go-up   go-down


65. Elsayes KM, Narra VR, Lewis JS Jr, Brown JJ: Magnetic resonance imaging of adrenal angiomyolipoma. J Comput Assist Tomogr; 2005 Jan-Feb;29(1):80-2
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiomyolipoma is a benign mesenchymal neoplasm that typically occurs in the kidney sporadically or in patients with tuberous sclerosis complex.
  • Other sites reported include the bone, colon, heart, lung, parotid gland, skin, spermatic cord, gynecologic regions, and retroperitoneum.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665688.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


66. John R, El-Rouby NM, Tomasetto C, Rio MC, Karam SM: Expression of TFF3 during multistep colon carcinogenesis. Histol Histopathol; 2007 07;22(7):743-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of TFF3 during multistep colon carcinogenesis.
  • The pathogenesis of colon cancer is not well understood.
  • This common type of cancer is generally believed to occur in a multistep process which involves alterations of various tumor suppressor genes and oncogenes during the progression through benign lesions towards carcinoma.
  • TFF3 is a product of the colonic epithelium and has been implicated in colonic mucosal protection and also in the aggressiveness of colon cancer cells.
  • The aim of this study was to analyze the expression of TFF3 during propagation towards cancer development in the human colon.
  • Colonic tissues representing colitis, adenomatous polyposis, tubulovillous adenoma, and mucoid/adeno-carcinomas were processed for immunohistochemistry using an antibody specific for human TFF3.
  • The results were correlated with those of PCNA-labeling, quantified, and compared with those of control tissues obtained from the safe margin of macroscopically normal colonic mucosa of patients with colon cancer.
  • Colonic tissues with highly invasive cancer cells were characterized by statistically significant down-regulation of TFF3 expression.
  • The changes observed in expression of TFF3 showed an inverse correlation with cell proliferation and suggest that it might play a protective role against colon carcinogenesis.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Adenoma, Villous / chemistry. Adenomatous Polyposis Coli / chemistry. Colitis / metabolism. Colonic Neoplasms / chemistry. Peptides / analysis
  • [MeSH-minor] Adult. Cell Proliferation. Cell Transformation, Neoplastic / chemistry. Colon / chemistry. Disease Progression. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Proliferating Cell Nuclear Antigen / analysis. Trefoil Factor-3

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17455148.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Peptides; 0 / Proliferating Cell Nuclear Antigen; 0 / TFF3 protein, human; 0 / Trefoil Factor-3
  •  go-up   go-down


67. Erkan M, Reiser-Erkan C, Michalski CW, Kleeff J: Tumor microenvironment and progression of pancreatic cancer. Exp Oncol; 2010 Sep;32(3):128-31
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor microenvironment and progression of pancreatic cancer.
  • Pancreatic ductal adenocarcinoma is characterized by « tumor desmoplasia », a remarkable increase in connective tissue that penetrates and envelopes the neoplasm.
  • It is becoming clear that this desmoplastic microenvironment of pancreatic cancer--which is forming approximately eighty percent of the tumor mass--is not a passive scaffold for the tumor cells but an active player in carcinogenesis.
  • Several chemotherapeutic agents and novel molecular targeted therapies against epithelial tumor cells--although showing antitumor activity in cell culture and mouse experiments--have failed to show significant effects in the clinic.
  • Thus, targeting pancreatic tumor cells alone seems unlikely to improve the dismal prognosis of pancreatic cancer.
  • Several primarily benign conditions associated with expansion of stromal and inflammatory components, such as chronic pancreatitis or hereditary pancreatitis are believed to increase the risk of pancreatic cancer.
  • Similar observations have been made in other cancer types such as chronic hepatitis-liver cancer, Barrett dyplasia-esophageal cancer, and inflammatory bowel disease-colon cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Pancreas / pathology. Pancreatic Neoplasms / metabolism. Tumor Microenvironment

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21403605.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ukraine
  •  go-up   go-down


68. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer; 2008 May-Jun;18(3):506-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer stem cells have been isolated from several solid tumors including prostate, colon, liver, breast, and ovarian cancer.
  • The aims of this study were to investigate the expression of the CD133-1 and CD133-2 epitopes in primary ovarian tumors and to biologically characterize CD133(+) ovarian cancer cells, also according to clinicopathologic parameters.
  • Tissue specimens were obtained at primary surgery from 41 ovarian carcinomas; eight normal ovaries and five benign ovarian tumors were also collected.
  • The percentages of CD133-1- and CD133-2-expressing cells were significantly lower in normal ovaries/benign tumors with respect to those in ovarian carcinoma.
  • CD133-1 and CD133-2 may be useful in order to select and enrich the population of CD133(+) ovarian tumor cells, which are characterized by a higher clonogenic efficiency and proliferative potential.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Glycoproteins / metabolism. Neoplasm Invasiveness / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Flow Cytometry. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868344.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


69. Mai PL, Korde L, Kramer J, Peters J, Mueller CM, Pfeiffer S, Stratakis CA, Pinto PA, Bratslavsky G, Merino M, Choyke P, Linehan WM, Greene MH: A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report. J Med Case Rep; 2007 Mar 28;1:9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report.
  • BACKGROUND: Germ-cell testicular cancer has not been definitively linked to any known hereditary cancer susceptibility disorder.
  • His evaluation as part of an etiologic study of familial testicular cancer revealed multiple colon polyps (adenomatous, hyperplastic, and hamartomatous) first found in his 50 s, multiple lipomas, multiple hyperpigmented skin lesions, left kidney cancer diagnosed at age 64, and a growth-hormone producing pituitary adenoma with associated acromegaly diagnosed at age 64.
  • The patient underwent genetic testing for Cowden syndrome (PTEN gene), Carney complex (PRKAR1A gene), and multiple endocrine neoplasia syndrome type 1 (MEN1 gene); no deleterious mutations were identified.
  • DISCUSSION: The constellation of benign and malignant neoplasms in the context of this patient's familial testicular cancer raised the possibility that these might be manifestations of a known hereditary susceptibility cancer syndrome; however, genetic testing for the three syndromes that were most likely to explain these findings did not show any mutation.
  • Alternatively, this family's phenotype might represent a novel neoplasm susceptibility disorder.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):629-31 [15799199.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:108-15 [15761242.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):476-90 [15667510.001]
  • [Cites] Dig Dis Sci. 2004 Apr;49(4):662-6 [15185875.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):363-71 [15172357.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):984-92 [12569597.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):413-8 [10701527.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Hum Mol Genet. 2006 Feb 1;15(3):443-51 [16407372.001]
  • (PMID = 17411461.001).
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / N02CP11019
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1847830
  •  go-up   go-down


70. Schwarz RE: Factors influencing change of preoperative treatment intent in a gastrointestinal cancer practice. World J Surg Oncol; 2007;5:32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Predominant reasons were proof of benign disease (n = 35), incomplete resection (R1 or R2, n = 23), unresectability by laparoscopy (n = 21) or laparotomy (n = 21), or others (n = 18).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Decision Making. Diagnosis, Differential. Endosonography. Female. Gastrointestinal Diseases / diagnosis. Gastrointestinal Diseases / mortality. Gastrointestinal Diseases / surgery. Humans. Immunohistochemistry. Laparoscopy. Logistic Models. Magnetic Resonance Imaging. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Patient Care Planning. Prognosis. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2004 Dec;199(6):1001-2 [15555990.001]
  • [Cites] Lancet. 2006 Mar 4;367(9512):754-65 [16517276.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Dis Colon Rectum. 2000 Nov;43(11):1606-27 [11089603.001]
  • [Cites] World J Surg. 2005 Oct;29(10):1210-6 [16136281.001]
  • [Cites] J Surg Oncol. 2006 Mar 1;93(3):199-205 [16482599.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):322-8; discussion 328-30 [10493479.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] J Gastrointest Surg. 1999 Jan-Feb;3(1):24-33 [10457320.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] J Am Coll Surg. 1997 Jan;184(1):9-15 [8989294.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):364-7 [2910444.001]
  • [Cites] J Clin Gastroenterol. 1988 Apr;10(2):130-2 [3047213.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):1013-21 [15194084.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):280-8 [15019924.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2117-27 [14645640.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):358-70; discussion 370-1 [14501502.001]
  • [Cites] Ann Surg Oncol. 2003 Jul;10(6):654-63 [12839850.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):696-703 [12167585.001]
  • [Cites] Oncologist. 2002;7(3):188-99 [12065790.001]
  • [Cites] Ann Surg Oncol. 2001 Sep;8(8):632-7 [11569777.001]
  • [Cites] Surgery. 2002 Jan;131(1):6-15 [11812957.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):392-9 [11882761.001]
  • (PMID = 17355626.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1838912
  • [General-notes] NLM/ Original DateCompleted: 20070813
  •  go-up   go-down


71. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K: Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer; 2006;5:62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The involvement of the cyclooxygenases (COX), in particular COX-2, is well documented for many tumours, e.g. colon, breast and prostate cancer, by both experimental and clinical studies.
  • One of the end products of PG-synthesis, PGE2, regulates several key-processes, which are characteristic for tumour growth, e.g. angiogenesis, proliferation and apoptosisis.
  • The present study investigated the pathway for PGE2-synthesis and signalling in ovarian tumourigenesis by analysing specimen from normal ovaries (n = 18), benign (B) (n = 8), borderline type (BL) (n = 6) and malignant tumours (AC) (n = 22).
  • IHC revealed staining of the tumour cells, but also increase of COX-1, COX-2, mPGES-1 and EP1-2 in the stromal compartment of AC (grades: moderately-, poorly- and undifferentiated).
  • This observation suggests interactions between tumour cells and stromal cells (fibroblasts, immune cells), e.g. paracrine signalling mediated by growth factors, cytokines and possibly PGs.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / metabolism. Densitometry. Disease Progression. Epithelial Cells / pathology. Female. Humans. Immunoblotting. Immunohistochemistry. Intramolecular Oxidoreductases / metabolism. Neoplasm Staging. Ovary / metabolism. Receptors, Prostaglandin E / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73 [12009392.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2002;21(2):149-53 [12086401.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1205-11 [12181243.001]
  • [Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):47-60 [12385833.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1423-9 [14508829.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1298-304 [14520463.001]
  • [Cites] Prog Lipid Res. 2004 Jan;43(1):3-35 [14636669.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8653-61 [14647459.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2607-23 [14669280.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):309-13 [14719060.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):538-45 [14760075.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):622-7 [14766256.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4670-9 [15269139.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Sep;83(9):783-95 [15315588.001]
  • [Cites] Reproduction. 2004 Nov;128(5):607-14 [15509706.001]
  • [Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]
  • [Cites] Gynecol Oncol. 1983 Dec;16(3):340-5 [6360817.001]
  • [Cites] Gynecol Obstet Invest. 1984;18(5):225-9 [6396175.001]
  • [Cites] Prostaglandins. 1985 May;29(5):665-72 [3859890.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):275-80 [9221804.001]
  • [Cites] J Histochem Cytochem. 1998 Jan;46(1):77-84 [9405496.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1240-8 [10098766.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10501-6 [10468638.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1927-33 [15870720.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Aug;73(2):103-11 [15963707.001]
  • [Cites] Oncogene. 2005 Dec 1;24(54):7991-8002 [16044148.001]
  • [Cites] Nucleic Acids Res. 2006;34(1):217-31 [16397300.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1884-91 [16287068.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2527-31 [16510568.001]
  • [Cites] Curr Pharm Des. 2006;12(8):943-54 [16533161.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Obstet Gynecol. 2005 Mar;192(3):819-25 [15746677.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):559-83 [15756426.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3735-44 [15867369.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3250-6 [15867220.001]
  • [Cites] J Reprod Fertil. 2000 Mar;118(2):375-85 [10864803.001]
  • [Cites] Epidemiology. 2000 Mar;11(2):111-7 [11021606.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:661-90 [11264472.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2328-34 [11280806.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Int J Mol Med. 2001 Jul;8(1):31-6 [11408945.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2496-504 [11489832.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7305-9 [11585770.001]
  • [Cites] Int J Mol Med. 2001 Dec;8(6):603-6 [11712072.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):202-9 [11801560.001]
  • [Cites] Annu Rev Physiol. 2002;64:69-92 [11826264.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):893-903 [11891188.001]
  • (PMID = 17107625.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Prostaglandin E; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC1657027
  •  go-up   go-down


72. Finger PT, Kurli M, Reddy S, Tena LB, Pavlick AC: Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol; 2005 Oct;89(10):1270-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In seven patients (13.4%) PET/CT imaging detected benign lesions in the bone, lung, lymph nodes, colon, and rectum.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / radiography. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Female. Fluorodeoxyglucose F18. Humans. Liver Neoplasms / radiography. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Spinal Neoplasms / radiography. Spinal Neoplasms / radionuclide imaging. Spinal Neoplasms / secondary. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 2001 May;119(5):670-6 [11346394.001]
  • [Cites] Eye (Lond). 1998;12 ( Pt 6):945-8 [10325992.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1797-803 [14602862.001]
  • [Cites] JAMA. 2003 Dec 24;290(24):3199-206 [14693872.001]
  • [Cites] J Nucl Med. 2004 Jan;45 Suppl 1:72S-81S [14736838.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):272-8 [14960647.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2438-44 [15197206.001]
  • [Cites] Br J Ophthalmol. 2004 Aug;88(8):1095-7 [15258035.001]
  • [Cites] Surv Ophthalmol. 2004 Sep-Oct;49(5):537-40 [15325198.001]
  • [Cites] Cancer. 1974 Oct;34(4):1001-4 [4424282.001]
  • [Cites] Arch Ophthalmol. 1982 Jun;100(6):939-40 [7092632.001]
  • [Cites] Arch Ophthalmol. 1986 Nov;104(11):1624-5 [3778275.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):383-9; discussion 390 [2023760.001]
  • [Cites] J Invest Dermatol. 1993 Mar;100(3):326S-331S [8440916.001]
  • [Cites] Arch Ophthalmol. 1996 Jan;114(1):107-8 [8540843.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2589-95 [9215829.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Jun;16(2):201-8 [9261748.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1151-9 [10091801.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2500-7 [12815135.001]
  • (PMID = 16170114.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC1772897
  •  go-up   go-down


73. Strum WB: Impact of a family history of colorectal cancer on age at diagnosis, anatomic location, and clinical characteristics of colorectal cancer. Int J Gastrointest Cancer; 2005;35(2):121-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The anatomic location of the cancer, presence of distal benign neoplasia when the cancer was proximal, and disease stage at diagnosis were not different between the groups.
  • CONCLUSIONS: Men with a family history of sporadic colorectal cancer and proximal colon cancer were younger than men without the family history and proximal colon cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15879626.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR00833
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


74. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A: Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med; 2009 Sep;1(6-7):338-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion.
  • Human colon cancers often start as benign adenomas through loss of APC, leading to enhanced beta CATENIN (beta CAT)/TCF function.
  • We find that epithelial cells of human colon carcinomas (CCs) and their stem cells of all stages harbour an active HH-GLI pathway.
  • Moreover, using a novel tumour cell competition assay we show that the self-renewal of CC stem cells in vivo relies on HH-GLI activity.
  • Targeting HH-GLI1, directly or indirectly, is thus predicted to decrease tumour bulk and eradicate CC stem cells and metastases.
  • [MeSH-major] Carcinoma / metabolism. Colonic Neoplasms / metabolism. Epithelial Cells / metabolism. Hedgehog Proteins / metabolism. Neoplastic Stem Cells / cytology. Transcription Factors / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cells, Cultured. Gene Expression Regulation, Neoplastic. Humans. Mice. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Signal Transduction / drug effects. Veratrum Alkaloids / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2006 Feb 20;233(1):117-23 [16473672.001]
  • [Cites] Virchows Arch. 2009 Apr;454(4):369-79 [19280222.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Development. 2001 Dec;128(24):5201-12 [11748155.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Development. 2004 Jan;131(2):337-45 [14681189.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] J Pathol. 2004 Aug;203(4):909-17 [15258993.001]
  • [Cites] Dev Biol. 2004 Sep 15;273(2):257-75 [15328011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Teratology. 1970 May;3(2):175-80 [4986632.001]
  • [Cites] Lipids. 1978 Oct;13(10):708-15 [723484.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):876-81 [9349822.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Development. 1999 Jun;126(14):3205-16 [10375510.001]
  • [Cites] Development. 2005 Jan;132(2):279-89 [15590741.001]
  • [Cites] Mech Dev. 2005 Feb;122(2):223-30 [15652709.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2187-2194.e1 [19324043.001]
  • [Cites] Surgery. 2006 May;139(5):665-70 [16701100.001]
  • [Cites] Gut. 2006 Jul;55(7):991-9 [16299030.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1238-9 [17287906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] World J Gastroenterol. 2007 Mar 21;13(11):1659-65 [17461467.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2622-7 [17683069.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):638-48 [17932721.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 [18765800.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):281-3 [18835029.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):603-7 [19092805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4254-9 [19246386.001]
  • [Cites] EMBO J. 2009 Mar 18;28(6):663-76 [19214186.001]
  • [CommentIn] EMBO Mol Med. 2010 Oct;2(10):385-6; author reply 386-7 [20721989.001]
  • [CommentIn] EMBO Mol Med. 2009 Sep;1(6-7):300-2 [20049733.001]
  • (PMID = 20049737.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ PMC3378144
  •  go-up   go-down


75. Remzi FH, Kirat HT, Geisler DP: Laparoscopic single-port colectomy for sigmoid cancer. Tech Coloproctol; 2010 Sep;14(3):253-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, we report a patient with a sigmoid colon cancer undergoing single-port laparoscopic sigmoid colectomy.
  • Colonoscopy performed 1 year after surgery showed no neoplasm or polyp identified.
  • CONCLUSION: Single-port laparoscopic surgery may allow common benign procedures via an incision in the umbilicus.
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Length of Stay. Middle Aged. Neoplasm Staging. Pain, Postoperative. Sigmoidoscopy / methods. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] Ann Surg. 2009 Apr;249(4):596-601 [19300230.001]
  • [Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]
  • [Cites] Surg Endosc. 2002 May;16(5):833-5 [11997832.001]
  • [Cites] Arch Surg. 2007 Sep;142(9):823-6; discussion 826-7 [17875836.001]
  • [Cites] Eur J Surg. 1999 Jan;165(1):29-34 [10069631.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 1999 Aug;9(4):361-4 [10488834.001]
  • [Cites] Ann Surg. 2009 Jan;249(1):77-81 [19106679.001]
  • [Cites] BJU Int. 2008 Jan;101(1):83-8 [18086101.001]
  • [Cites] Dis Colon Rectum. 2009 Apr;52(4):558-66 [19404053.001]
  • [Cites] Surg Endosc. 2003 May;17(5):828-30 [12582763.001]
  • [Cites] Urology. 2008 Jan;71(1):3-6 [18242353.001]
  • [Cites] Endoscopy. 2007 Oct;39(10):913-5 [17968809.001]
  • [Cites] Arch Surg. 2009 Feb;144(2):173-9; discussion 179 [19221330.001]
  • (PMID = 19953288.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


76. Lim GH, Koh DC, Cheong WK, Wong KS, Tsang CB: Natural history of small, "indeterminate" hepatic lesions in patients with colorectal cancer. Dis Colon Rectum; 2009 Aug;52(8):1487-91
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-one (89.1%) of these were shown to be stable lesions that were likely benign.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prevalence. Prognosis. Retrospective Studies. Singapore / epidemiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617765.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Metaxas G, Tangalos A, Pappa P, Papageorgiou I: Mucinous cystic neoplasms of the mesentery: a case report and review of the literature. World J Surg Oncol; 2009;7:47

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There have been rare reports involving the mesentery as a primary tumour site.
  • At laparotomy, the mass was fixed within the colonic mesentery.
  • Histology demonstrated a benign mucinous cystadenoma.
  • METHODS AND RESULTS: We review the literature on mucinous cystic neoplasms of the mesentery and report on the pathogenesis, biologic behavior, diagnosis and treatment of similar extra-ovarian tumors.
  • We propose an updated classification of mesenteric cysts and cystic tumors.
  • CONCLUSION: Mucinous cystic neoplasms of the mesentery present almost exclusively in women and must be considered in the differential diagnosis of mesenteric tumors.
  • Only full histological examination of a mucinous cystic neoplasm can exclude a borderline or malignant component.
  • An updated classification of mesenteric cysts and cystic tumors is proposed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol Surv. 1972 Mar;27(3):133-46 [4614139.001]
  • [Cites] Am J Surg. 1975 Jun;129(6):709-11 [1130615.001]
  • [Cites] Obstet Gynecol. 1977 Apr;49(4):486-8 [854250.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Cancer. 1979 Aug;44(2):692-8 [476578.001]
  • [Cites] Conn Med. 1980 Mar;44(3):140-1 [7363617.001]
  • [Cites] Arch Surg. 1984 Jul;119(7):838-42 [6732494.001]
  • [Cites] Ann Surg. 1986 Jan;203(1):109-12 [3942415.001]
  • [Cites] Gynecol Oncol. 1986 May;24(1):103-12 [3699572.001]
  • [Cites] Arch Pathol Lab Med. 1987 Mar;111(3):282-4 [3827533.001]
  • [Cites] Radiology. 1987 Aug;164(2):327-32 [3299483.001]
  • [Cites] Obstet Gynecol. 1988 Jun;71(6 Pt 2):1030-2 [3374916.001]
  • [Cites] Histopathology. 1988 May;12(5):527-32 [3397046.001]
  • [Cites] Pathologica. 1989 Jul-Aug;81(1074):381-401 [2696922.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):903-8 [1415909.001]
  • [Cites] Radiographics. 1992 Nov;12(6):1051-68 [1439011.001]
  • [Cites] South Med J. 1993 Feb;86(2):173-6 [8434287.001]
  • [Cites] Pancreas. 1993 Sep;8(5):647-9 [8302802.001]
  • [Cites] Int J Gynecol Pathol. 1994 Jan;13(1):73-9 [8112958.001]
  • [Cites] Surg Laparosc Endosc. 1994 Feb;4(1):59-61 [8167868.001]
  • [Cites] Radiographics. 1994 Jul;14(4):729-37 [7938764.001]
  • [Cites] Am J Gastroenterol. 1994 Nov;89(11):2085-7 [7942747.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1078-91 [7943529.001]
  • [Cites] Aust N Z J Surg. 1994 Nov;64(11):741-4 [7945079.001]
  • [Cites] Eur J Surg Oncol. 1997 Feb;23(1):88-90 [9066755.001]
  • [Cites] Eur J Surg. 1997 Sep;163(9):673-7 [9311474.001]
  • [Cites] Pathol Int. 1997 Nov;47(11):806-8 [9413043.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):698-703 [9630176.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):1-16 [9888699.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Dig Dis Sci. 1999 Apr;44(4):768-74 [10219836.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Surg Endosc. 1999 Sep;13(9):937-9 [10449859.001]
  • [Cites] Br Med J. 1953 Jun 13;1(4823):1316 [13042235.001]
  • [Cites] Ginekol Pol. 2004 Jul;75(7):545-7 [15517775.001]
  • [Cites] Surg Clin North Am. 1950 Aug;30(4):1081-96 [15442870.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1320-7 [10555000.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):269-74 [10587182.001]
  • [Cites] Eur J Surg. 2000 Mar;166(3):262-4 [10755343.001]
  • [Cites] Surgery. 2000 Jun;127(6):707-8 [10840368.001]
  • [Cites] J Am Assoc Gynecol Laparosc. 2000 Aug;7(3):429-31 [10924644.001]
  • [Cites] Dig Surg. 2000;17(4):323-8 [11053936.001]
  • [Cites] Eur J Pediatr Surg. 2000 Dec;10(6):402-3 [11215785.001]
  • [Cites] Surg Endosc. 2000 Jun;14(6):595 [11265068.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Nov;2(11):1026-31 [15551256.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jan;24(1):4-25 [15626914.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jan-Feb;29(1):74-9 [15665687.001]
  • [Cites] J Am Coll Surg. 2005 May;200(5):727-33 [15848365.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):62-70 [15923171.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):927-31 [16112012.001]
  • [Cites] Surg Infect (Larchmt). 2005;6(2):259-61 [16128633.001]
  • [Cites] Pathol Int. 2006 Feb;56(2):71-7 [16445818.001]
  • [Cites] Ann Trop Med Parasitol. 2006 Mar;100(2):137-42 [16492361.001]
  • [Cites] Hepatogastroenterology. 2006 Mar-Apr;53(68):286-90 [16608041.001]
  • [Cites] Dig Dis Sci. 2006 Mar;51(3):629-32 [16614979.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):655-7 [16731606.001]
  • [Cites] Dig Surg. 2006;23(3):186-91 [16837797.001]
  • [Cites] Gastrointest Endosc. 2006 Nov;64(5):697-702 [17055859.001]
  • [Cites] Arch Pathol Lab Med. 2006 Nov;130(11):1715-7 [17076537.001]
  • [Cites] World J Surg. 2006 Dec;30(12):2236-45 [17103100.001]
  • [Cites] Urol Oncol. 2007 Jan-Feb;25(1):53-5 [17208139.001]
  • [Cites] Ulus Travma Acil Cerrahi Derg. 2007 Jan;13(1):74-7 [17310417.001]
  • [Cites] World J Surg. 2007 Mar;31(3):542-8 [17318706.001]
  • [Cites] Indian J Gastroenterol. 2007 May-Jun;26(3):137-8 [17704584.001]
  • [Cites] JOP. 2007;8(5):553-63 [17873459.001]
  • [Cites] Can J Surg. 2007 Oct;50(5):E3-4 [18031625.001]
  • [Cites] Eur J Pediatr Surg. 2007 Dec;17(6):400-3 [18072024.001]
  • [Cites] Eur J Surg Oncol. 2008 Feb;34(2):196-201 [17524597.001]
  • [Cites] Pediatr Dev Pathol. 2008 Jan-Feb;11(1):46-9 [18237233.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):401-4 [17957438.001]
  • [Cites] Ann Surg. 2008 Apr;247(4):571-9 [18362619.001]
  • [Cites] World J Gastroenterol. 2008 Apr 14;14(14):2280-3 [18407611.001]
  • [Cites] Am J Surg Pathol. 2008 May;32(5):645-55 [18344868.001]
  • [Cites] Acta Chir Belg. 2008 May-Jun;108(3):354-5 [18710115.001]
  • [Cites] Anticancer Res. 2008 Jul-Aug;28(4C):2309-15 [18751411.001]
  • [Cites] Pathol Int. 2008 Sep;58(9):601-5 [18801076.001]
  • [Cites] World J Gastroenterol. 2008 Oct 7;14(37):5769-72 [18837099.001]
  • [Cites] Am J Clin Oncol. 2008 Oct;31(5):519-20 [18838891.001]
  • [Cites] Dig Liver Dis. 2008 Nov;40(11):837-46 [18499541.001]
  • [Cites] Emerg Radiol. 2009 Jul;16(4):327-30 [18604575.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2001 Oct;98(10):1179-84 [11680992.001]
  • [Cites] Acta Cytol. 2001 Nov-Dec;45(6):941-7 [11726122.001]
  • [Cites] Surg Today. 2001;31(10):920-2 [11759891.001]
  • [Cites] World J Surg. 2002 Apr;26(4):462-9 [11910481.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):219 [11961656.001]
  • [Cites] Pancreatology. 2002;2(4):413-20 [12138231.001]
  • [Cites] Langenbecks Arch Surg. 2002 Nov;387(7-8):281-5 [12447553.001]
  • [Cites] Pathol Int. 2002 Oct;52(10):648-52 [12445137.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):45-57 [12533639.001]
  • [Cites] Radiographics. 2003 Mar-Apr;23(2):457-73; quiz 535-6 [12640160.001]
  • [Cites] J Gastroenterol. 2003;38(3):278-82 [12673452.001]
  • [Cites] Oncol Rep. 2003 May-Jun;10(3):515-25 [12684617.001]
  • [Cites] Acta Med Austriaca. 2003;30(2):61-4 [12752092.001]
  • [Cites] Acta Chir Belg. 2003 Jun;103(3):329-31 [12914373.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1221-8 [12960806.001]
  • [Cites] Ann Clin Lab Sci. 2003 Fall;33(4):465-70 [14584762.001]
  • [Cites] Ann Thorac Surg. 2003 Nov;76(5):1738-40 [14602331.001]
  • [Cites] Scand J Gastroenterol. 2003 Nov;38(11):1193-5 [14686726.001]
  • [Cites] Surg Endosc. 2003 Dec;17(12):2036 [14973761.001]
  • [Cites] J Reprod Med. 2004 Jan;49(1):65-7 [14976800.001]
  • [Cites] Ann Diagn Pathol. 2004 Apr;8(2):96-101 [15060888.001]
  • [Cites] Pathol Int. 2004 May;54(5):355-9 [15086841.001]
  • [Cites] J Urol. 2004 Jul;172(1):146-7 [15201756.001]
  • [Cites] Minerva Chir. 2004 Aug;59(4):405-11 [15278036.001]
  • [Cites] Radiographics. 2004 Sep-Oct;24(5):1353-65 [15371613.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1412-4 [15484358.001]
  • [Cites] Pathol Int. 2004 Oct;54(10):781-6 [15482568.001]
  • [Cites] Ann Surg. 1973 Jul;178(1):13-9 [4717705.001]
  • (PMID = 19454018.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 111
  • [Other-IDs] NLM/ PMC2691402
  •  go-up   go-down


78. Li Q, Gao C, Juzi JT, Hao X: Analysis of 82 cases of retroperitoneal schwannoma. ANZ J Surg; 2007 Apr;77(4):237-40
Genetic Alliance. consumer health - Schwannoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients (2.4%) had multiple schwannomas and two others had a simultaneous malignancy (adenocarcinoma of the ascending colon and squamous-cell carcinoma of the lung, respectively).
  • Pathological results showed 81 (98.8%) were benign schwannoma and 1 (1.2%) was a malignant one.
  • The tumour size ranged from 3 to 22 cm.
  • One benign schwannoma recurred 3 years after the operation.
  • CONCLUSION: Most of the retroperitoneal schwannomas are benign.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388825.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


79. Catalano O, De Lutio di Castelguidone E, Nunziata A, De Rosa V, Siani A: Gastrointestinal stromal tumours: Pictorial review. Radiol Med; 2005 Nov-Dec;110(5-6):484-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They normally involve the stomach, the small bowel, or the colon.
  • GISTs are immunohistochemically identified by the expression of the c-kit protein, which is not detected in other mesenchymal tumours.
  • Smaller lesions, which are usually benign, tend to be well-defined, relatively homogeneous, and with intraluminal growth.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Neoplasm Metastasis / radiography. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437034.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 19
  •  go-up   go-down


80. Tedesco MM, Curet MJ: Laparoscopic-assisted colectomy for colon cancer. Expert Rev Med Devices; 2006 Jul;3(4):415-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic-assisted colectomy for colon cancer.
  • Laparoscopic-assisted colectomy (LAC) for colon cancer was first described in 1991.
  • Unlike other laparoscopic procedures used to treat benign disease, the LAC for colon cancer has been slow to gain acceptance for a variety of reasons.
  • Recently, several large, randomized controlled trials have demonstrated that LACs are comparable with open colectomies with respect to oncological issues such as survival, port-site metastases and tumor recurrence.
  • Moreover, there are significant patient benefits with the use of LAC including duration of analgesic use, return of bowel function, length of stay and return to normal activity.
  • [MeSH-major] Colectomy. Colonic Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Humans. Length of Stay. Neoplasm Recurrence, Local. Quality of Life. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866638.001).
  • [ISSN] 1743-4440
  • [Journal-full-title] Expert review of medical devices
  • [ISO-abbreviation] Expert Rev Med Devices
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


81. Jiang B, Ren T, Dong B, Qu L, Jin G, Li J, Qu H, Meng L, Liu C, Wu J, Shou C: Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients. Am J Pathol; 2010 Sep;177(3):1095-103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients.
  • Tumor-associated antigens, which induce the generation of autoantibodies, are useful as cancer biomarkers in early detection and prognostic prediction of cancer.
  • To isolate a novel cancer marker, we used serum antibodies from colon cancer patients to screen a phage display peptide library.
  • A positive peptide 249C (VPLYSNTLRYGF) that could specifically react with serum from colon cancer patients was isolated, and the corresponding antigen-human arrest defective 1 (ARD1A), which shares an identical LYSNTL motif with 249C, was identified.
  • Using ELISA and immunohistochemistry, we found anti-ARD1A antibody levels in serum from patients with colon cancer were significantly higher than those in healthy volunteers (P < 0.001), and ARD1A expression was detected in 84.1% (227/270) of colon cancer tissues compared with 22.7% (55/242) of matched noncancerous tissues (P < 0.001) and 4.8% (2/42) of benign lesions (P < 0.001).
  • These results indicate that ARD1A is a novel tumor-associated antigen and a potential prognostic factor for colon cancer.
  • [MeSH-major] Acetyltransferases / blood. Antigens, Neoplasm / blood. Autoantibodies / blood. Colonic Neoplasms / blood. Colonic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biomarkers, Tumor / isolation & purification. Blotting, Western. Cell Line, Tumor. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Epitopes / isolation & purification. Humans. Kaplan-Meier Estimate. Middle Aged. N-Terminal Acetyltransferase A. N-Terminal Acetyltransferase E. Prognosis. Proportional Hazards Models

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31132-40 [15994306.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):17749-57 [15755738.001]
  • [Cites] Thyroid. 2005 Oct;15(10):1131-6 [16279846.001]
  • [Cites] Oncogene. 2006 Jul 20;25(31):4350-60 [16518407.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10677-82 [17108104.001]
  • [Cites] J Cell Biol. 2007 Nov 19;179(4):619-26 [17998402.001]
  • [Cites] Cancer Lett. 2008 Jun 8;264(1):83-92 [18325661.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1296-310 [18471507.001]
  • [Cites] Histopathology. 2009 Feb;54(3):309-18 [19236507.001]
  • [Cites] Biochem J. 2009 Apr 1;419(1):133-9 [18973474.001]
  • [Cites] Oncol Rep. 2009 Apr;21(4):909-15 [19287988.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1777-88 [10766157.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5 [11274429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15209-14 [11742062.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):636-43 [12079511.001]
  • [Cites] Cell. 2002 Nov 27;111(5):709-20 [12464182.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):57-63 [12496764.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):73-84 [12532422.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:4 [12747765.001]
  • [Cites] Proteomics. 2004 Sep;4(9):2572-82 [15352232.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):16-20 [7505195.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):725-9 [8642276.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3363-7 [9363867.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2158-66 [10090922.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4656-62 [15536075.001]
  • [Cites] Biochem J. 2005 Mar 15;386(Pt 3):433-43 [15496142.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1224-35 [16177248.001]
  • (PMID = 20639454.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Epitopes; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.88 / N-Terminal Acetyltransferase A; EC 2.3.1.88 / N-Terminal Acetyltransferase E; EC 2.3.1.88 / NAA10 protein, human
  • [Other-IDs] NLM/ PMC2928944
  •  go-up   go-down


82. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn; 2005 Aug;7(3):413-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both benign and malignant tumors represent heterogenous tissue containing tumor cells and non-neoplastic mesenchymal and inflammatory cells.
  • In addition, Pyrosequencing proved superior to dideoxy sequencing in the detection of KRAS mutations from DNA mixtures of paraffin-embedded colon cancer and normal tissue as well as from paraffin-embedded pancreatic cancers.
  • It is particularly useful for tumors containing abundant non-neoplastic cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol. 2001 Mar;8(3):243-52 [11306349.001]
  • [Cites] Clin Chem. 2002 Mar;48(3):428-35 [11861435.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):227-34 [11895870.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5261-6 [11959976.001]
  • [Cites] Hum Mutat. 2002 May;19(5):479-85 [11968080.001]
  • [Cites] J Mol Diagn. 2002 Nov;4(4):185-90 [12411585.001]
  • [Cites] Clin Chem. 2002 Dec;48(12):2164-70 [12446472.001]
  • [Cites] Electrophoresis. 2002 Dec;23(24):4072-9 [12481262.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):152-6 [12866415.001]
  • [Cites] J Mol Diagn. 2003 Nov;5(4):243-9 [14573784.001]
  • [Cites] Mol Biotechnol. 2004 Feb;26(2):147-64 [14764940.001]
  • [Cites] Nucleic Acids Res. 2004;32(5):e53 [15037663.001]
  • [Cites] Hum Mutat. 2004 May;23(5):406-12 [15108270.001]
  • [Cites] Hum Mutat. 2004 May;23(5):437-41 [15108274.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:250-6 [15251969.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):236-42 [15269301.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5847-51 [1631067.001]
  • [Cites] Biotechniques. 1994 May;16(5):938-43 [8068351.001]
  • [Cites] J Clin Pathol. 1994 Dec;47(12):1082-4 [7876379.001]
  • [Cites] J Pathol. 1996 Jul;179(3):254-9 [8774479.001]
  • [Cites] Clin Chem. 1996 Sep;42(9):1382-90 [8787693.001]
  • [Cites] Diagn Mol Pathol. 1996 Dec;5(4):260-4 [8955617.001]
  • [Cites] Anal Biochem. 1997 May 1;247(2):394-403 [9177704.001]
  • [Cites] J Immunol Methods. 1997 Aug 7;206(1-2):11-9 [9328563.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):373-9 [9708798.001]
  • [Cites] Curr Opin Biotechnol. 1998 Dec;9(6):602-8 [9889145.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):83-95 [9916922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41 [10430926.001]
  • [Cites] Biotechniques. 2000 Jan;28(1):140-4, 146-7 [10649785.001]
  • [Cites] Gene. 2000 Aug 8;253(2):249-57 [10940563.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1929-38 [11106325.001]
  • [Cites] Genome Res. 2001 Jan;11(1):3-11 [11156611.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):105-10 [15681481.001]
  • (PMID = 16049314.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / PHS HHS / / P01-9467802; United States / PHS HHS / / P01-9483703; United States / PHS HHS / / R01-9485602
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC1867544
  •  go-up   go-down


83. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Determination of SirT1 function in tumor cells is important for its targeting in cancer therapy.
  • We found that SirT1 knockdown by short hairpin RNA accelerates tumor xenograft formation by HCT116 cells, whereas SirT1 overexpression inhibits tumor formation.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.
  • These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


84. Rosin D, Zmora O, Hoffman A, Khaikin M, Munz Y, Zakai BB, Goldes Y, Shabtai EL, Shabtai M, Ayalon A: [Laparoscopic colon and rectal surgery--after ten years and 350 operations]. Harefuah; 2007 Mar;146(3):176-80, 247-8
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic colon and rectal surgery--after ten years and 350 operations].
  • Laparoscopic colon and rectal surgery has not yet been adopted by the majority of surgeons, due to technical complexity and reservation regarding its oncological safety.
  • We present our experience with laparoscopic surgery of the large bowel over the last ten years.
  • AIM: To assess the short and intermediate term results after laparoscopic colon and rectal surgery, and to summarize the long term results after curative colectomy for malignancy.
  • METHODS: Data regarding all patients undergoing laparoscopic colon and rectal surgery was prospectively entered into a computerized database, including demographics, surgical technique and perioperative course.
  • RESULTS: Over a period of ten years, 350 various laparoscopic colon and rectal procedures were performed, for both benign and malignant conditions.
  • CONCLUSIONS: The laparoscopic approach to large bowel surgery enables short and long term results comparable with those achieved by open technique, regarding perioperative complication rate and long term oncologic outcome.
  • [MeSH-major] Colonic Neoplasms / surgery. Laparoscopy. Rectal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Infection / epidemiology. Infection / mortality. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Postoperative Complications / epidemiology. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460920.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


85. Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res; 2005 Feb 1;11(3):1203-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.
  • Colon cancer is the third leading cause of cancer-related death in the United States, affecting approximately 147,000 people each year.
  • Most colon cancers arise from benign neoplasms and evolve into adenocarcinomas through a stepwise histologic progression sequence that starts from adenomas or hyperplastic polyps/serrated adenomas.
  • Genetic alterations and, more recently, epigenetic alterations have been associated with specific steps in this polyp-adenocarcinoma sequence and likely drive the histologic progression of colon cancer.
  • Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.
  • These results show that aberrant methylated genes can be detected frequently in sporadic colon polyps and that they can be detected in fecal DNA.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenoma / genetics. Adenoma / pathology. Carrier Proteins. Cell Line, Tumor. CpG Islands / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Feces / chemistry. Humans. Hyperplasia. Neoplasm Proteins / genetics. Nuclear Proteins. O(6)-Methylguanine-DNA Methyltransferase / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709190.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 95103; United States / NCI NIH HHS / CA / U01 CA 094986
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


86. Chung SH, Park YS, Jo YJ, Kim SH, Jun DW, Son BK, Jung JY, Baek DH, Kim DH, Jung YY, Lee WM: Asymptomatic lymphangioma involving the spleen and retroperitoneum in adults. World J Gastroenterol; 2009 Nov 28;15(44):5620-3
Genetic Alliance. consumer health - Lymphangioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphangioma, a benign neoplasm of the lymphatic system, is common in children but rare in adults.
  • We report a cystic lymphangioma of the spleen and retroperitoneum, which was incidentally found in a 56-year-old man who was hospitalized due to a colon mass.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1998 Mar;85(3):395-7 [9529502.001]
  • [Cites] Surg Today. 2001;31(3):258-61 [11318134.001]
  • [Cites] Asian J Surg. 2006 Jan;29(1):51-4 [16428102.001]
  • [Cites] Radiographics. 2004 Sep-Oct;24(5):1353-65 [15371613.001]
  • [Cites] Radiology. 1997 Jan;202(1):173-6 [8988208.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):483-8 [12828616.001]
  • (PMID = 19938204.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2785067
  •  go-up   go-down


87. Kumar S, Fitzmaurice GJ, O'Donnell ME, Brown R: Acute right iliac fossa pain: not always appendicitis or a caecal tumour: two case reports. Cases J; 2009;2(1):88

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute right iliac fossa pain: not always appendicitis or a caecal tumour: two case reports.
  • BACKGROUND: A solitary diverticulum of the caecum is a rare benign condition which was first described by Potier in 1912 1.
  • The presence of multiple diverticula, caecal phlegmon, or the inability to rule out an underlying caecal neoplasm warrants a right hemicolectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Esp Enferm Dig. 2006 Nov;98(11):875-80 [17198478.001]
  • [Cites] Ann R Coll Surg Engl. 2006 Nov;88(7):672-4 [17132320.001]
  • [Cites] Ulster Med J. 2005 Sep;74(2):132-3 [16235768.001]
  • [Cites] Ann Chir Gynaecol Suppl. 1977;66(5):230-3 [413467.001]
  • [Cites] J Am Coll Surg. 1999 Jun;188(6):629-34; discussion 634-5 [10359355.001]
  • [Cites] Am Surg. 1987 Jan;53(1):41-5 [3099619.001]
  • [Cites] Dis Colon Rectum. 1978 Nov-Dec;21(8):627-9 [104852.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s116-8 [15655592.001]
  • (PMID = 19173712.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2637256
  •  go-up   go-down


88. Gravante G, Delogu D, Venditti D: Colosigmoid adenocarcinoma anastomotic recurrence seeding into a transsphincteric fistula-in-ano: a clinical report and literature review. Surg Laparosc Endosc Percutan Tech; 2008 Aug;18(4):407-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the case of a left colon adenocarcinoma anastomotic recurrence that metastasized to a benign transsphincteric fistula-in-ano, presumably through the implantation of viable malignant cells shed from the secondary tumor, and discuss the implications of these findings in colorectal cancer surgery.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasm Recurrence, Local / pathology. Neoplasm Seeding. Rectal Fistula / pathology. Rectal Neoplasms / secondary. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716545.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


89. Bretthauer M, Hoff G: [Prevention and early diagnosis of colorectal cancer]. Tidsskr Nor Laegeforen; 2007 Oct 18;127(20):2688-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CRC develops from benign adenomas in the colon over a long time.
  • MATERIAL AND METHODS: Medline was systematically searched using the MeSH terms "Colorectal neoplasm AND prevention and control", with a limitation on randomised trials in humans.
  • [MeSH-minor] Colon / radiography. Colonoscopy. Early Diagnosis. Evidence-Based Medicine. Humans. Mass Screening. Occult Blood. Prognosis. Randomized Controlled Trials as Topic. Sigmoidoscopy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952153.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 35
  •  go-up   go-down


90. Li G, Passebosc-Faure K, Feng G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C: MN/CA9: a potential gene marker for detection of malignant cells in effusions. Biomarkers; 2007 Mar-Apr;12(2):214-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of malignant cells in effusions has implications in diagnosis, tumour staging and prognosis.
  • MN/CA9 has proved to be a valuable marker in many cancers such as lung, breast, colon, kidney, etc.
  • Seventy-one pleural effusions including 59 malignant effusions from patients with cancer, and 12 patients with benign diseases as a control, were subjected to RT-PCR for detection of MN/CA9 gene expression.
  • MN/CA9 gene expression was detected in 53/59 (89.8%) pleural effusions from cancer patients (15/16 for breast cancers, 10/11 for lung cancers, 4/4 for ovary cancers, 2/3 for colon-rectal cancers, 5/6 for cancers of unknown site, 7/8 for mesothelioma and 10/11 for other cancers).
  • [MeSH-major] Antigens, Neoplasm / analysis. Carbonic Anhydrases / analysis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Case-Control Studies. Gene Expression. Humans. Neoplasm Proteins / analysis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536770.001).
  • [ISSN] 1354-750X
  • [Journal-full-title] Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • [ISO-abbreviation] Biomarkers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


91. Goldstein NS: Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases. Am J Clin Pathol; 2006 Jan;125(1):132-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases.
  • Eight sessile serrated adenoma (SSA), right colon polypectomies with focal invasive adenocarcinoma or high-grade dysplasia were studied to identify features indicating a high risk of transformation and characterize the morphologic features of serrated dysplasia; 6 cases had invasive adenocarcinoma; 2 were high-grade dysplasia.
  • All 8 cases had an abrupt transition from benign to high-grade in situ or invasive malignancy.
  • In the 6 invasive adenocarcinomas, the neoplasm extended directly down into the submucosa without lateral intramucosal spread.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Chromosomal Instability. Colonic Neoplasms / pathology. Microsatellite Repeats
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Aged. Aged, 80 and over. Carrier Proteins / analysis. Cell Transformation, Neoplastic / pathology. Colonic Polyps / pathology. Epithelium / pathology. Humans. Middle Aged. Nuclear Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16483002.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Nuclear Proteins
  •  go-up   go-down


92. Sánchez A, Muñoz C, Bujanda L, Iriondo C, Gil-Molet A, Cosme A, Sarasqueta C, Echenique-Elizondo M: The value of colonoscopy to assess rectal bleeding in patients referred from Primary Care Units. Rev Esp Enferm Dig; 2005 Dec;97(12):870-6
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is produced mainly because of benign disease originating in the anus and the rectum.
  • Severe disease was encountered in 22 patients (neoplasm, angiodysplasia, and inflammatory bowel disease); 10 patients had polyps, 6 had colorectal cancer, and 6 had inflammatory bowel disease.
  • Out of 63 patients younger than 50 years, 5 had severe disease, all of them in the form of inflammatory bowel disease.
  • CONCLUSIONS: A neoplasm of the rectum and colon in patients younger than 50 years is a rare event.
  • A colonoscopy must be performed in this group of patients to rule out inflammatory bowel disease.

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454606.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


93. Birkenkamp-Demtröder K, Wagner L, Brandt Sørensen F, Bording Astrup L, Gartner W, Scherübl H, Heine B, Christiansen P, Ørntoft TF: Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology; 2005;82(2):121-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our previous microarray-based studies identified secretagogin to be highly expressed in normal colon mucosa compared to basal expression in colon adenocarcinomas.
  • The aim of this study was to analyze the differential expression of secretagogin in normal mucosa, adenocarcinomas, and neuroendocrine tumors.
  • Tissues adjacent to benign hyperplasic polyps and adenomas showed a decreased number of secretagogin-expressing neuroendocrine cells.
  • Secretagogin co-localized with neuroendocrine markers (chromogranin A, neuron-specific enolase, synaptophysin) in neuroendocrine cells in crypts of normal mucosa, and in tumor cells of carcinoids.
  • Secretagogin was strongly expressed in the cytosol and the nucleus of 19 well-differentiated neuroendocrine carcinoids and carcinoid metastases, as well as in neuroendocrine tumors from the lung, pancreas and adrenal gland.
  • Combined immunohistochemical analysis of secretagogin and FK506-binding protein 65, a protein de novo synthesized in adenocarcinomas, distinguished well-differentiated carcinoids, adenocarcinoids and undifferentiated carcinomas.
  • [MeSH-major] Calcium-Binding Proteins / metabolism. Neuroendocrine Tumors / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Blotting, Western. Carcinoid Tumor / metabolism. Carcinoid Tumor / pathology. Cell Differentiation / physiology. Chromogranin A. Chromogranins / metabolism. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Male. Microscopy, Fluorescence. Middle Aged. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Peptidylprolyl Isomerase / metabolism. Phosphopyruvate Hydratase / metabolism. Secretagogins. Synaptophysin / metabolism. Tacrolimus Binding Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16449819.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Chromogranin A; 0 / Chromogranins; 0 / SCGN protein, human; 0 / Secretagogins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase; EC 5.2.1.- / Tacrolimus Binding Proteins; EC 5.2.1.8 / FKBP10 protein, human; EC 5.2.1.8 / Peptidylprolyl Isomerase
  •  go-up   go-down


94. Holten-Andersen MN, Hansen U, Brünner N, Nielsen HJ, Illemann M, Nielsen BS: Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer; 2005 Jan 10;113(2):198-206
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To clarify the role of TIMP-1 in colorectal tumorigenesis, the expression pattern of TIMP-1 in benign and malignant colorectal tumors was studied.
  • No TIMP-1 mRNA was seen in any of the cases in benign or malignant epithelial cells, in vascular cells or smooth muscle cells.
  • In conclusion, TIMP-1 expression is a rare event in benign human colon tissue but is highly expressed by myofibroblasts in association with invading colon cancer cells.
  • [MeSH-minor] Case-Control Studies. Cell Transformation, Neoplastic. Diagnosis, Differential. Fibroblasts / physiology. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Neoplasm Invasiveness. RNA, Messenger / analysis. RNA, Messenger / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386409.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1
  •  go-up   go-down


95. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary neoplasms after radiotherapy for a childhood solid tumor.
  • This study was conducted to determine the outcome of patients who develop a second neoplasm after radiotherapy (RT) for a childhood solid tumor.
  • From 1956 to 1998, 429 children with a malignant solid tumor were treated at a single radiation oncology facility.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • There were 14 malignant neoplasms in 13 (3.0%) and 14 benign neoplasms in 11 patients (2.6%).
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • Only 5 (36%) of the 14 benign tumors occurred in the RT field, with osteochondroma being the most common.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804994.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Doll D, Keller L, Maak M, Boulesteix AL, Siewert JR, Holzmann B, Janssen KP: Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival. Int J Colorectal Dis; 2010 May;25(5):573-81
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival.
  • However, their contribution to tumor formation remains incompletely understood.
  • The aim of the present study was to investigate the regulation of their expression in colon cancer cells and to test the hypothesis that altered CXC-chemokine expression is related to critical clinical parameters, such as survival or metastasis formation.
  • MATERIALS AND METHODS: Expression levels of interleukin-8 (CXCL-8) and growth-related oncogenes 2 and 3 (GRO-2/CXCL-2 and GRO-3/CXCL-3) were quantified using qRT-PCR in 97 patients with completely resected colon carcinoma and correlated with clinical parameters.
  • Moreover, 16 samples of normal mucosa, nine samples of benign adenoma, and 11 samples of liver metastasis were analyzed.
  • Next, the regulation of chemokine expression in response to various stimuli was tested in colon cancer cell lines (HT29, HCT116, CaCO2).
  • RESULTS: Expression of GRO-2, GRO-3, and IL-8 was significantly increased in colon cancer as compared to normal colon tissue.
  • Expression of GRO-2 and GRO-3 was already enhanced in premalignant adenomas, and GRO-3 was significantly down-regulated in liver metastasis as compared to the primary tumor.
  • Finally, all chemokines were strongly induced by IL-1alpha in the colon cancer cell lines tested, indicating a potential link to inflammatory processes.
  • CONCLUSION: In accordance with earlier findings, we report here a significantly increased expression of GRO-2, GRO-3, and IL-8 in colon carcinoma as compared to normal tissue.
  • [MeSH-major] Chemokine CXCL2 / genetics. Chemokines, CXC / genetics. Colonic Neoplasms / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Interleukin-8 / genetics. Liver Neoplasms / secondary
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Leukoc Biol. 2002 Nov;72(5):847-55 [12429706.001]
  • [Cites] ILAR J. 1999 Sep;40(4):175-182 [11406696.001]
  • [Cites] J Gastroenterol. 1994 Aug;29(4):423-9 [7951851.001]
  • [Cites] J Lab Clin Med. 1998 Aug;132(2):97-103 [9708570.001]
  • [Cites] World J Gastroenterol. 2007 Oct 7;13(37):4996-5002 [17854143.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3581-4 [16101183.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):27348-57 [7592998.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3298-304 [11595728.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):437-43 [15734970.001]
  • [Cites] Melanoma Res. 1999 Aug;9(4):383-7 [10504057.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1712-7 [17253102.001]
  • [Cites] Am J Pathol. 1992 Aug;141(2):397-407 [1497091.001]
  • [Cites] Hepatogastroenterology. 2003 Nov-Dec;50(54):1910-3 [14696431.001]
  • [Cites] Int J Colorectal Dis. 2005 Sep;20(5):391-402 [15883783.001]
  • [Cites] J Cell Biochem. 1988 Feb;36(2):185-98 [3356754.001]
  • [Cites] Cancer Immunol Immunother. 1994 Mar;38(3):167-70 [8124684.001]
  • [Cites] Biochemistry. 1997 Mar 4;36(9):2716-23 [9054580.001]
  • [Cites] Melanoma Res. 1995 Jun;5(3):179-81 [7640519.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):783-9 [10213213.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1214-23 [9322516.001]
  • [Cites] J Exp Med. 1995 Dec 1;182(6):2069-77 [7500052.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):492-504 [12145803.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3711-21 [10589791.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2290-9 [10786697.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):317-22 [15958053.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):20431-7 [11923281.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5951-9 [17062666.001]
  • [Cites] Exp Dermatol. 1998 Dec;7(6):335-41 [9858136.001]
  • [Cites] Surg Oncol. 1992 Aug;1(4):323-9 [1341267.001]
  • [Cites] Endocr Relat Cancer. 2007 Dec;14(4):1039-52 [18045955.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2735-40 [10914718.001]
  • [Cites] J Leukoc Biol. 1997 Nov;62(5):554-62 [9365108.001]
  • [Cites] Cytokine. 2000 Jan;12(1):78-85 [10623446.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2747-56 [17363596.001]
  • [Cites] Mol Med. 2001 Aug;7(8):523-34 [11591888.001]
  • [Cites] Cancer Lett. 2008 Aug 28;267(2):226-44 [18579287.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):481-95 [15563311.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1970-6 [15545974.001]
  • [Cites] J Exp Med. 1997 Oct 20;186(8):1201-12 [9334359.001]
  • [Cites] Clin Exp Metastasis. 2004;21(7):571-9 [15787094.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5346-55 [17000667.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12085-93 [12556523.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5269-77 [11046061.001]
  • [Cites] Cytokines. 1992;4:96-116 [1335322.001]
  • (PMID = 20162422.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CXCL2 protein, human; 0 / CXCL3 protein, human; 0 / Chemokine CXCL2; 0 / Chemokines, CXC; 0 / Interleukin-8
  •  go-up   go-down


97. Leman ES, Schoen RE, Weissfeld JL, Cannon GW, Sokoll LJ, Chan DW, Getzenberg RH: Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res; 2007 Jun 15;67(12):5600-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers.
  • Colon cancer-specific antigen (CCSA)-3 and CCSA-4 are novel colon cancer markers identified by focused proteomic analysis of nuclear structural proteins.
  • Serum samples from 107 subjects undergoing colonoscopy, 28 subjects with colorectal cancer, and 125 subjects with benign disease or other types of cancer were evaluated.
  • Individuals who underwent colonoscopy were classified into mutually exclusive categories, including normal colon, hyperplastic polyp, nonadvanced adenoma, and advanced adenoma.
  • [MeSH-major] Adenocarcinoma / blood. Adenoma / blood. Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Colonic Neoplasms / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 3.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Schoen RE, Weissfeld JL, Sokoll LJ, Chan DW, Cannon GW, Getzenberg RH. Cancer Res. 2013 Jan 15;73(2):1034 [23271721.001]
  • (PMID = 17575123.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084968
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / colon-specific antigen
  •  go-up   go-down


98. Bussom S, Saif MW: Intraductal papillary mucinous neoplasia (IPMN). Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP; 2010;11(2):131-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasia (IPMN). Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
  • The diagnosis and treatment of intraductal papillary mucinous tumors (IPMN) of the pancreas has evolved over the last decade.
  • IPMN is a disease of the ductal epithelium and represent a spectrum of disease, ranging from benign to malignant lesions, making the early detection and characterization of these lesions important.
  • As with villous adenomas of the colon, not all IPMNs will develop into adenocarcinoma.
  • Definitive management is surgical resection for appropriate candidates, as benign lesions harbor malignant potential.
  • [MeSH-minor] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Carcinoma, Papillary / classification. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Congresses as Topic. Cyst Fluid / chemistry. Cytokines / analysis. Early Detection of Cancer / methods. Enzyme-Linked Immunosorbent Assay. Gastrointestinal Neoplasms / diagnosis. Humans. Models, Biological. Neoplasm Staging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20208320.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 26
  •  go-up   go-down


99. Touzios J, Ludwig KA: Local management of rectal neoplasia. Clin Colon Rectal Surg; 2008 Nov;21(4):291-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local management of rectal neoplasia.
  • The treatment of rectal neoplasia, whether benign or malignant, challenges the surgeon.
  • Any effective treatment aimed at controlling rectal cancer in the pelvis must take into account the disease in the bowel wall itself and the disease, or potential disease, in the mesorectum.
  • Without removing both the rectum and the mesorectum there is no completely accurate way to determine whether a rectal cancer has moved outside the bowel wall, so any decision on local management of a rectal neoplasm is a calculated risk.
  • For benign neoplasia, the challenge is removing the lesion without having to resort to a major abdominal procedure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2006 May;32(4):420-5 [16520014.001]
  • [Cites] Dis Colon Rectum. 2006 Feb;49(2):164-8 [16362801.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):271 [17103255.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):322-6 [1728363.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):63-9; discussion 69-70 [1733375.001]
  • [Cites] Ann Surg. 2007 May;245(5):726-33 [17457165.001]
  • [Cites] Am J Surg. 1990 Sep;160(3):306-12 [2203268.001]
  • [Cites] Dis Colon Rectum. 1990 Sep;33(9):735-9 [2390908.001]
  • [Cites] Surg Endosc. 1989;3(2):96-9 [2672395.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):219-23 [2910430.001]
  • [Cites] South Med J. 1987 Jan;80(1):41-3 [3798186.001]
  • [Cites] Br J Surg. 1985 Sep;72(9):694-7 [4041727.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1286-95 [7497841.001]
  • [Cites] Dis Colon Rectum. 1995 Oct;38(10):1093-6 [7555426.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):177-81 [7851173.001]
  • [Cites] Dis Colon Rectum. 1995 Mar;38(3):233-8 [7882783.001]
  • [Cites] Dis Colon Rectum. 1994 Jan;37(1):52-7 [8287748.001]
  • [Cites] Dis Colon Rectum. 1993 Feb;36(2):127-34 [8425415.001]
  • [Cites] Dis Colon Rectum. 1993 Apr;36(4):405-9 [8458271.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Dis Colon Rectum. 1997 Apr;40(4):388-92 [9106685.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1472-6 [9407987.001]
  • [Cites] Dis Colon Rectum. 1977 Sep;20(6):467-72 [902542.001]
  • [Cites] Surg Endosc. 1988;2(4):245-50 [3071872.001]
  • [Cites] Am J Surg. 1987 Jan;153(1):41-7 [3799891.001]
  • [Cites] Surgery. 1980 May;87(5):549-51 [7368104.001]
  • [Cites] Cancer. 1980 Jun 15;45(12):2965-8 [7388739.001]
  • [Cites] Surg Annu. 1977;9:171-94 [882892.001]
  • [Cites] Dis Colon Rectum. 1977 Sep;20(6):463-6 [902541.001]
  • [Cites] Dis Colon Rectum. 1999 Jun;42(6):770-5 [10378601.001]
  • [Cites] Dis Colon Rectum. 1999 Jul;42(7):881-5 [10411434.001]
  • [Cites] Ann Surg Oncol. 1999 Jul-Aug;6(5):433-41 [10458680.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):313-22 [10661337.001]
  • [Cites] Int J Colorectal Dis. 2000 Feb;15(1):9-20 [10766086.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):200-6 [11852333.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1170-4 [12209248.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):522-29; discussion 529-30 [12368681.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):457-9 [15048747.001]
  • [Cites] Surg Endosc. 2004 Jul;18(7):1075-8 [15156388.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):711-7; discussion 717-8 [15383798.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):711-9; discussion 719-21 [15768186.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):808-16 [15784023.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1169-75 [15793645.001]
  • [Cites] Recent Results Cancer Res. 2005;165:46-57 [15865020.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1380-8 [15906120.001]
  • [Cites] J Surg Oncol. 2006 Sep 1;94(3):194-202 [16900535.001]
  • (PMID = 20011441.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780249
  • [Keywords] NOTNLM ; Cancer / neoplasms / rectum / transanal / villous adenoma
  •  go-up   go-down


100. Schildhaus HU, Büttner R, Binot E, Merkelbach-Bruse S, Wardelmann E: [Inflammatory fibroid polyps are true neoplasms with PDGFRA mutations]. Pathologe; 2009 Dec;30 Suppl 2:117-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IFP occur in the stomach, small bowel, colon and esophagus.
  • METHODS: A total of 29 IFP originating in the stomach, small bowel and colon were examined immunohistochemically, and mutational analyses of PDGFRA exons 10, 12, 14 and 18 were conducted.
  • The mutational types are related to mutations known from gastrointestinal stromal tumors (GIST).
  • Our data indicate that IFP are true neoplasms (true benign tumors) and not reactive lesions.
  • [MeSH-minor] Antigens, CD34 / genetics. Cell Division / genetics. Exons / genetics. Female. Gastric Mucosa / pathology. Gastrointestinal Stromal Tumors / genetics. Gastrointestinal Stromal Tumors / pathology. Gene Expression Regulation, Neoplastic / genetics. Humans. Intestinal Mucosa / pathology. Male. Mucous Membrane / pathology. Neoplasm Invasiveness / pathology. Polymerase Chain Reaction. Polymorphism, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Gastroenteritis.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):767-8 [14991958.001]
  • [Cites] Am J Pathol. 1949 May;25(3):397-411 [18127133.001]
  • [Cites] Lab Invest. 2006 Jan;86(1):94-100 [16258521.001]
  • [Cites] Intern Med. 2007;46(12):855-8 [17575378.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] J Pathol. 2008 Oct;216(2):176-82 [18686281.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5357-64 [15928335.001]
  • [Cites] Histopathology. 2005 Feb;46(2):166-75 [15693889.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14344-9 [16186508.001]
  • [Cites] Endoscopy. 1990 Sep;22(5):203-7 [2242737.001]
  • [Cites] Surg Gynecol Obstet. 1953 Mar;96(3):335-67 [13038651.001]
  • [Cites] Diagn Cytopathol. 2003 Apr;28(4):217-21 [12672099.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):874-83 [15146165.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):197-204 [15269295.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):664-71 [16357008.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Mar;12(1):59-66 [15163021.001]
  • (PMID = 19756614.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down






Advertisement